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This work as a whole is dedicated to those who suffer with post-viral chronic fatigue, in 
hopes that one day we will have a cure. 
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INTRODUCTION: Human gammaherpesvirus (GHV) infections, such as with Epstein-
Barr Virus (EBV), are associated with fatigue and elevated concentrations of cytokines.  
Murine GHV-68 (MuGHV) has been used as a model of EBV.  However, the behavioral 
impact of infection with MuGHV is unknown.   
METHODS I: Male C57BL/6J mice (25 – 28 g at time of surgery) were housed in cages 
containing running wheels and infrared detectors to measure activity.  Mice were 
administered vehicle intranasally (I.N.) at dark onset and recordings of EEG, body 
temperature and activity were made for 4 days.  Mice were inoculated I.N. at dark onset 
with 400 PFU (n=13) or 40,000 PFU (n=8) of MuGHV and recordings continued for 30 
days.  Mice were then injected intraperitoneally (I.P.) at dark onset with vehicle and 24 h 
control recordings obtained.  The mice were injected I.P. with lipopolysaccharide (LPS) 
and recordings continued for 5 days.   
METHODS II. Mice housed in the same conditions were inoculated I.N. with vehicle and 
sacrificed after 4 days or inoculated with 400 PFU or with 40,000 PFU MuGHV and 
sacrificed 5, 9, or 26 days after inoculation.  Brain tissue, blood, spleen, and lung were 
collected, and stored at -80 °C until assay. 
RESULTS I.  Infected mice showed decreases in wheel running activity, core body 
temperature, food intake and body weight.  Mice inoculated with 40,000 PFU of MuGHV 
 ix 
 x 
had increases in NREM sleep, sleep fragmentation, and wakefulness during the peak of 
viral replication.  Responses of infected mice to LPS were exacerbated.  
RESULTS II:  Cytokine concentrations and profiles in brain and the periphery were 
altered during infection.  The alterations in cytokine profiles differed in a complex 
manner depending on dose of MuGHV.      
CONCLUSIONS:  Based upon reductions in wheel running, these results indicate that 
mice become chronically fatigued during infection with MuGHV.  Chronic infection is 
associated with long-term changes in thermoregulatory mechanisms and the ability of the 
immune system to respond normally to subsequent challenge. Virus-induced alterations 
in central cytokine profiles with respect to those in the periphery suggest potential 
mechanisms that may lead to fatigue.  These studies demonstrate the utility of MuGHV 








Chronic fatigue and Epstein-Barr Virus 
Chronic fatigue is a widespread, disabling symptom that decreases quality of life 
and productivity in the workplace (Bombardier & Buchwald, 1996).  While the etiology 
of chronic fatigue syndrome (CFS) remains elusive, it is often hypothesized that many 
patients develop symptoms of CFS after an infection with a gammaherpesvirus (GHV) 
such as Epstein-Barr virus (EBV).  Chronic fatigue can be triggered by many factors, 
including viral or bacterial infection, surgery, or depression (Afari & Buchwald, 2003).  
If fatigue is not attributed to a primary illness, is severe and unremitting for a period of 
six months or more, and is not substantially alleviated by rest, it is classified as chronic 
fatigue syndrome (CFS) (Fukuda et al., 1994).  In CFS, chronic fatigue can be 
accompanied by symptoms such as sore throat, lymph node pain, muscle pain, joint pain, 
headache, and memory difficulties (Afari et al., 2003; Fukuda et al., 1994).  Most CFS 
patients complain of disrupted sleep, including difficulty maintaining sleep, a need for 
daytime naps, and feeling unrefreshed upon awakening, as well as mental health issues 
such as anxiety and depression (Buchwald, Pascualy, Bombardier, & Kith, 1994; 
Moldofsky, 1989).  It is estimated that CFS affects approximately 800,000 Americans of 
all socioeconomic classes and also affects relatively equal amounts of men and women.  
 1 
The annual economic impact of CFS is estimated at $9.1 billion due to loss of 
productivity (Reynolds, Vernon, Bouchery, & Reeves, 2004), however its impact due to 
depression as a result of chronic fatigue is still unknown.  In addition, individuals with 
chronic fatigue and CFS are reported to make an average of 21 primary care visits per 
person each year, which poses a large burden on the health care system (Bombardier et 
al., 1996). CFS leads to a higher degree of impairment than other chronic illnesses 
(Bombardier et al., 1996) and there are very few effective treatments available (Afari et 
al., 2003).  Chronic fatigue and CFS are difficult to study in humans due to the 
heterogeneous patient population and the variety of triggering events (Afari et al., 2003; 
Evans, 1991; Krupp, Mendelson, & Friedman, 1991; Kyle & DeShazo, 1992). 
EBV is a ubiquitous human GHV that establishes life-long latency.  The 
hypothesis that EBV is involved in CFS derives, in part, from observations that 
individuals with CFS have higher antibody titers to EBV (Glaser et al., 2005; Matthews, 
Lane, & Manu, 1991; Swanink et al., 1995).  Though some studies do not demonstrate a 
relationship between EBV and CFS (Buchwald, Pearlman, Umali, Schmaling, & Katon, 
1996; Koelle et al., 2002; Mawle et al., 1995), the numbers of CFS patients with high 
EBV titers may be under-represented due to poor test specificity, variation in viral gene 
expression, and low viral gene expression during the latent period (Glaser et al., 2005).  
Data indicate that 95% of all adults have antibodies against EBV (Rickinson & Kieff, 
2001; Mandell, Bennett, & Dolin, 1995).  Transmission of EBV can occur through blood 
products, transplantation, saliva, and sexual activity (Mandell et al., 1995), which makes 
prevention of the spread of this virus extremely challenging.  Vaccination efforts have not 
been successful due to EBV’s complex stages and protein expression, mainly the 
 2 
variability in latency phenotypes of EBV (Khanna, Moss, & Burrows, 1999; Khanna, 
Burrows, & Moss, 1995; Cohen, 2000), and medical interventions are rather ineffective 
in decreasing symptom severity (Gershburg & Pagano, 2005).  Thus a large proportion of 
the general population is at risk for post-viral fatigue in response to EBV, and also at risk 
for developing depression as a result of fatigue.  Many studies suggest EBV may be 
central to the pathogenesis of CFS and may perpetuate the chronic state of fatigue (Glaser 
& Kiecolt-Glaser, 1998; Jones, 1988; Natelson et al., 1994).   
Pro-inflammatory cytokines, such as IL-1β, TNFα, IFN-γ, and IL-6 and are 
principle mediators of the effects of GHV infection (Sarawar, Lee, & Giannoni, 2004).  
These cytokines also induce sickness behavior, as manifest by fatigue, fever, malaise, and 
arthralgia (Dantzer, 2001; Dantzer et al., 1998; Dantzer et al., 1999a; Vollmer-Conna et 
al., 2004).  In addition to their role in sickness behavior after an immune challenge, these 
pro-inflammatory cytokines regulate and/or modulate normal sleep (Opp, 2005).  Patients 
with CFS have higher IL-1 and IL-6 levels that coincide with periods of fatigue (Cannon 
et al., 1999).  This relationship among IL-1, IL-6 and fatigue does not appear in either 
normal subjects or CFS patients during exercise-induced fatigue (Gupta, Aggarwal, & 
Starr, 1999).  In addition, patients with CFS report poor quality of sleep, including 
insomnia, awakenings during the night, and unrefreshing sleep (Unger et al., 2004; 
Fukuda et al., 1994).  It is possible that elevated circulating cytokines during EBV 
infection result in CFS and the post-viral symptoms of fatigue and daytime sleepiness.  
The following studies will address this concept. 
It is difficult to study EBV and post-viral chronic fatigue in humans due to the 
heterogeneity of the patient population (age, stage of infection, variable gene expression 
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during latency, unpredictability of fatigue trigger, and the time of infection), and subject 
sampling methods (Glaser et al., 2005).  In addition, fatigue can be subjective and is 
assessed through self-report (Hossain et al., 2005).  Fatigue is also difficult to assess in 
animals (Hossain et al., 2005).  Previously published animal models of chronic fatigue 
have used bacterial or viral infections, such as Brucella abortus, Cryptosporidium 
parvum or influenza virus (Sheng, Hu, Lamkin, Peterson, & Chao, 1996; Ottenweller et 
al., 1998), as the infectious agent, or have used non-infectious challenges such as 2’-
deoxyuridine 5’triphosphosphatase (dUTPase, an enzyme encoded by EBV) (Glaser et 
al., 2005; Fleischmann, Kremmer, Greenspan, Grasser, & Niedobitek, 2002).  Brucella or 
influenza virus do not produce latent infections, and repeated administration of dUTPase 
does not constitute a true infection.  As such, these challenges are unable to model many 
of the sequelae that are concomitant with chronic viral infection.  Furthermore, these 
previously reported studies have primarily focused on immune responses, and not the 
relationships between immune responses and behavior.  These projects focused on 
cytokines as mediators of fatigue in response to viral infection.  The following 
experiments assessed sleep-wake behavior, fatigue, and cytokine profiles of mice infected 
with MuGHV during both active and latent stages of viral infection.  These studies also 
determined the impact of a secondary immune challenge on mice in the latent phase of 
infection with this virus. 
 
Relevance to Mental Health 
Fatigue is a hallmark symptom of depression and is reported in about 66% of 
patients diagnosed with depression (Johnson, 2005).  In population studies, depression 
 4 
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generally predicts fatigue, and conversely fatigue predicts onset of depression (Johnson, 
2005).  In addition, anxiety and depression are frequently comorbid symptoms in subjects 
suffering from chronic fatigue syndrome (Kirmayer, Robbins, Dworkind, & Yaffe, 1993).  
Cytokines are implicated as mediators of fatigue as well as the onset and maintenance of 
depression (Dantzer, Wollman, Vitkovic, & Yirmiya, 1999b).  Cytokines induce 
behavioral changes that are consistent with depression in humans (Anisman & Merali, 
1999,Dantzer et al., 1999b) high levels of circulating cytokines are found in patients with 
depression, and administration of cytokines into healthy volunteers induces depressive-
like symptoms and fatigue (Maier & Watkins, 2000).  Similarly, healthy volunteers report 
anxiety and depressive-like feelings after endotoxin administration, and the magnitude 
and extent of these feelings directly correlate with the secretion of TNF-α and IL-6 
(Reichenberg et al., 2001).  Finally, cytokines can induce fatigue, and fatigue itself may 
lead to depression (Johnson, 2005).  However, the mechanisms by which cytokines, 
fatigue, and depression interact remain largely unknown.  By elucidating potential 
mechanistic contributions of cytokines to post-viral fatigue using an animal model, these 
studies have furthered the understanding of the relationships among cytokines, fatigue, 
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MURINE GAMMAHERPESVIRUS 68: A MODEL FOR THE STUDY OF 
EPSTEIN-BARR VIRUS INFECTIONS AND RELATED DISEASES.1 
 
Abstract 
Gammaherpesviruses (GHVs) are double-stranded DNA viruses that cause acute 
disease and then persist in the body in a latent form (Ackermann, 2006). Like other 
herpesviruses, GHVs (Table 1) are classified based on their genome organization 
(Ackermann, 2006) and are composed of a large double-stranded linear DNA genome 
encased in a protein capsid that is in turn wrapped in a lipid bilayer membrane envelope 
(Damania, Choi, & Jung, 2000). Epstein-Barr virus (EBV) is a ubiquitous human GHV 
that causes both acute and chronic disease (Cohen, 2000). The molecular biology of EBV 
has been characterized extensively by use of in vitro systems (Callan, 2004; D'Addario, 
Ahmad, Morgan, & Menezes, 2000; Haan, et al., 2001). The strong species specificity of 
GHVs has precluded using human GHVs in animal models, making the study of their 
pathogenesis difficult. However, in 1980, a murine GHV (MuGHV, also known as 
MHV68 and  γHV68) was identified as a natural pathogen of bank voles (Clethrionomys 
glareolus) and wood mice (Apodemus flavicollis) that was able to infect laboratory mice 
                                                 
1 This chapter was published in its entirety.  The complete citation is: 
Olivadoti, M, Toth, LA, Weinberg, J, Opp, MR (2007).  Murine gammaherpesvirus 68: a model for 
the study of Epstein-Barr virus infections and related diseases.  Comparative Medicine, 57(1):44-50. 
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{BLASKOVIC1980}. Experimental MuGHV infections in laboratory mice share many 
features of EBV infections in humans, including facets of the clinical human syndrome 
known as infectious mononucleosis (Flano, Woodland, & Blackman, 2002). These 
features make MuGHV a valuable experimental model for studying the pathophysiology 
of a GHV in a natural host.  
 
Epstein-Barr virus  
EBV (also known as human herpesvirus 4) is a ubiquitous human virus that 
infects B cells in humans and New World nonhuman primates (Ackermann, 2006).  In 
humans, EBV causes acute disease and establishes life-long latency (Rickinson & Kieff, 
2001).  EBV infections are associated with the syndrome known as infectious 
mononucleosis and, less frequently, with the development of B-cell lymphoproliferative 
disorders, several malignancies—including Burkitt lymphoma, Hodgkin disease, and 
nasopharyngeal carcinoma—and lymphomatoid granulomatosis, a form of chronic lung 
disease (Table 2) (Iwatsuki et al., 2004).  About 95% of the United States population has 
been exposed to and carries antibodies against EBV (Rickinson et al., 2001).  Despite 
humoral and cellular immune responses by the host, EBV nonetheless establishes latent 
infection (Stevenson & Efstathiou, 2005).  
Routes of transmission for EBV include blood products, organ transplantation, 
saliva, and sexual activity (Hess, 2004). In the susceptible host, EBV establishes an initial 
lytic infection in the lung epithelium that resolves within days. This acute phase is 
followed by the establishment of a lifelong latent state, predominantly in the B cell 
compartment in the spleen, with latency maintained under the control of the host immune 
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system. Reactivation allows infectious virus particles to spread from B cells to the 
oropharyngeal mucosa, where virus can be shed and transmitted to new hosts (Stevenson 
et al., 2005; Damania et al., 2000).  
During the lytic phase of infection, EBV uses several mechanisms to evade host 
defense processes. EBV enters neutrophils, penetrating the nucleus and triggering 
apoptosis (Larochelle, Flamand, Gourde, Beauchamp, & Gosselein, 1998).  In addition, 
EBV infection reduces the phagocytic activity of monocytes, interferes with the function 
of dendritic cells, and inhibits differentiation of monocytes into mature dendritic cells 
(Levitsky & Masucci, 2002).  EBV infection also triggers the secretion of interleukin (IL) 
8 and macrophage inflammatory protein 1α (MIP1α), which attract both B and T cells to 
the site of inflammation (McColl, Roberge, Larochelle, & Gosselin, 1997), thereby 
increasing the pool of cellular targets for viral infection.  
EBV modulates T lymphocyte responses by suppressing the production of antigen 
receptors on effector T cells (Chen et al., 2001).  In this manner, EBV establishes an 
immunoprivileged site for persistence in secondary lymphoid tissue and respiratory 
epithelium (Chen et al., 2001).  In latent EBV infection, viral gene expression is restricted 
and reduced (Levitsky et al., 2002).  An important factor in this process is transformation 
of the linear viral genome into the circular form known as an episome. The episomal 
configuration limits translation and expression of viral proteins, thereby limiting the 
presentation of viral epitopes to T cells, curtailing expression of signals that would trigger 
a host response, and allowing the virus to remain undetected in cells (Callan, 2004; 
(Flano, Woodland, & Blackman, 2002); Flano, Kim, Moore, Woodland, & Blackman, 
2003). If host immune cells do recognize the virus, the virus can, in turn, inhibit antigen 
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processing via a Gly–Ala repeat in EBV nuclear antigen 1 that alters the kinetics of 
antigen processing and prevents apoptosis of latently infected cells (Lagunoff & Carroll, 
2003; Levitskaya, Sharipo, Leonchiks, Ciechanover, & Masucci, 1997). 
Although the molecular biology of EBV has been characterized extensively, 
infection-induced disease and its pathogenesis are difficult to study in EBV-infected 
human populations due to the chronic and latent properties of the virus, human variation 
in environment and genetics, the well-documented impact of stressors on viral 
recrudescence, ethical concerns, and the complexity of the symptoms. For example, EBV 
infection in humans often is associated with fatigue and excessive sleepiness (Ablashi, 
1994; Guilleminault, 1989; Josephs et al., 2000; Schumann et al., 1990; White et al., 
2001).  Such symptoms could be related to immune stimulation or dysfunction, neural-
endocrine homeostatic imbalance, or both, as produced secondary to acute and chronic 
viral infection (Cleare, 2003; Papanicolaou et al., 2004).  However, the pathogenesis, 
progression, and therapy of complex and debilitating symptoms like fatigue and 
nonrestorative sleep are difficult to study in human populations with EBV. Therefore, 
using a mouse model to study the pathogenesis of fatigue and sleepiness in relation to 
latent viral infection and immune dysfunction would be highly beneficial for 
understanding the mechanisms that link GHVs and fatigue. GHVs are highly species-
specific; thus EBV does not infect laboratory mice (Haan, Aiyar, & Longnecker, 2001).  
Nonhuman primates can be infected with a rhesus lymphocryptovirus, a related 
gammaherpesvirus, but marked differences in the progression of the infection complicate 
its use as a model for EBV (Moghaddam et al., 1997).  A valid animal model of GHV 
infection would facilitate the study of associated pathogenesis and disease states by 
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allowing control and evaluation of host factors (such as genetics and environment) and 
the assessment of pathogenic features as the disease progresses. In the following sections, 
we discuss similarities of EBV and MuGHV that make MuGHV-infected mice useful for 




 MuGHV was identified in 1980 (Blaskovic, Stancekova, Svobodova, & 
Mistrikova, 1980) in 2 species of rodents (A. flavicollis and C. glareolus) and was shown 
to readily infect several strains of laboratory mice (Blaskovic et al., 1980; Rajcani et al., 
1985).  The virus was classified as a GHV in light of the sequence and organization of the 
viral genome and its virion architecture (Table 1) (Virgin et al., 1997).  MuGHV shares 
important structural and biologic features with human GHVs, including EBV (Nash & 
Sunil-Chandra, 1994; Virgin et al., 1997).  MuGHV and EBV have common blocks of 
conserved genes and are similar in terms of establishment and clearance of the acute 
infection, establishment of latency, and the immunologic responses they elicit in the host. 
In addition, MuGHV and EBV both show epithelial and B-cell tropism, virus-driven B-
cell activation and proliferation, and a syndrome of acute infectious mononucleosis 
(Flano et al., 2002; Nash et al., 1994).   Because an in vivo system is essential to studying 
the complex interplay between infection, immunology, and disease symptoms, including 
disease-related behavioral changes, MuGHV is a valuable experimental model for 
studying the pathophysiology and related behavioral outcomes of GHV infections in 
vivo.  
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Genetics and immune evasion strategies of MuGHV. The MuGHV viral genome 
is a linear double-stranded DNA molecule consisting of 118,237 basepairs of virally 
unique sequences flanked by multiple copies of 1213-basepair terminal repeats that 
encode for at least 100 viral proteins (Virgin et al., 1997).  Within the genome, 80 of 
these genes are largely colinear with the EBV genome (Virgin et al., 1997).  The genome 
is encased in a nucleocapsid and encodes several membrane proteins that allow the virus 
to enter the host cell, avoid immune targeting, and move from one cell to another (Bortz 
et al., 2003).  In addition, the MuGHV genome encodes virus-specific open reading 
frames that are shared by EBV, including genes that are considered important for viral 
tropism, latency, and transformation (Virgin et al., 1997).  These proteins regulate the 
expression of viral genes, facilitate replication of viral DNA, and influence host immune 
responses (Virgin et al., 1997).  The receptors used by MuGHV remain unknown.  
Although the natural route of MuGHV infection has not yet been defined, the 
respiratory route is presumed to be the main method of transmission for MuGHV. 
However, virus transmission between infected and uninfected laboratory mice housed 
together has not been reported, to our knowledge. Whether transmission in research 
settings failed due to differences between laboratory and wild rodents, attenuation of 
laboratory stocks of virus, or other factors is unknown. Adult laboratory mice inoculated 
intranasally with MuGHV develop an initial infection in alveolar epithelial and 
pulmonary mononuclear cells, both of which also are involved in EBV infection 
(Ackermann, 2006).  Other studies have used intraperitoneal injection of virus; this 
method generates similar splenic peak viral loads as does intranasal inoculation across a 
wide range of doses (Tibbetts, McClellan, Gangappa, Speck, & Virgin, 2003b).  Viral 
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dosages range from 0.1 to 106 plaque forming units (PFU) without appreciable mortality, 
and route of infection and viral dose do not appear to affect latent viral titers in the spleen 
(Tibbetts et al., 2003b).  The efficacy of wide dose ranges and various routes of 
administration facilitate the use of MuGHV as a model for studying the effects of a GHV 
on host immune responses and associated behavioral changes, such as the fatigue and 
altered sleep that accompany human EBV infections. 
The acute phase of MuGHV infection includes production of infectious virus in 
and lysis of alveolar epithelial cells. Viral titers in the lung peak between days 5 and 10 
after infection, and viral clearance in the lung occurs within 9 to 15 d after infection 
(Cardin, Brooks, Sarawar, & Doherty, 1996; Tibbetts et al., 2003a) (Figure 1).  The acute 
(lytic) phase of infection generates a host inflammatory response in the lung that persists 
for as long as 30 d after infection. Monocytosis and macrophage activation peak at 3 d 
after infection, eliciting the production of IL12, the resultant production of interferon 
(IFN) γ, and subsequent T cell activation (Elsawa & Bost, 2004) These processes 
promote pulmonary viral clearance, leukocytosis, and splenomegaly (Dutia et al., 2004; 
Elsawa et al., 2004; Sunil-Chandra, Efstathiou, Arno, & Nash, 1992).  CD8+ T cells with 
Vβ4+ markers dominate the early stages of viral infection, although the degree of 
expansion varies with the haplotype of the major histocompatibility complex (Pivik et al., 
1993; Hardy et al., 2001).  Analysis of recombinant inbred mice revealed 2 quantitative 
trait loci that are associated with the magnitude of Vβ4+CD8+ T cell expansion, which is 
involved in lymphocytosis (Hardy et al., 2001).  
Like EBV, MuGHV uses various mechanisms to curtail the host defenses, 
allowing for lifelong infection. For example, the M11 protein inhibits apoptosis, and 
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RCA inhibits complement activation (Wang & Barks, 1999)(Kapadia, Molina, van, V, 
Speck, & Virgin, 1999).  MuGHV potentially inhibits inflammatory chemokine responses 
via a chemokine-binding protein, M3, which can delay or decrease the host’s response to 
the virus (van, V et al., 2002).  The M3 protein also causes the failure of localization of 
memory CD8+ T cells to sites of virus reactivation (Obar et al., 2004).  In addition, 
MuGHV induces the release of endogenous IL10, which limits the leukocytosis of B cells 
infected with the virus (Peacock & Bost, 2001).  Therefore like EBV, MuGHV uses 
immune evasion strategies that modulate inflammatory responses and facilitate viral 
replication. 
Latent infection and chronic disease. Like other herpesviruses, MuGHV can 
maintain long-term latency in its host. Although the pulmonary inflammation generated 
in response to lytic infection resolves during the second week, coincident with viral 
clearance from the lung (Elsawa et al., 2004), antigen persists in the lungs for as long as 
30 d after infection, suggesting long-term persistence of the virus (Sunil-Chandra, 
Efstathiou, Arno, & Nash, 1992).  Spleen, lymph nodes, and bone marrow also harbor 
latent virus, primarily in B lymphocytes, macrophages, and dendritic cells (Flano, 
Husain, Sample, Woodland, & Blackman, 2000; Flano et al., 2003; Flano et al., 2002; 
Sunil-Chandra et al., 1992).  In the spleen, latent virus is maintained in all 3 of these cell 
types for at least 3 mo after infection, with the highest frequencies in memory and 
germinal center B cells (Flano et al., 2005).  Relatively constant numbers of latently 
infected B cells are present in the spleen at different times over the lifespan of MuGHV-
infected mice (Tripp et al., 1997).  
After intranasal infection with MuGHV, pulmonary titers of lytic virus detected 
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by plaque assay peak between days 6 to 9, and lytic virus is cleared by days 10 to 14 
(Flano et al., 2003).  However, between 10,000 and 100,000 cells in the lung carry the 
viral DNA by day 3 after infection (Flano et al., 2003).  This frequency is essentially 
unchanged for at least 21 d (Flano et al., 2003).  An analysis of sorted populations of lung 
cells (B cells, macrophages, dendritic cells, and ‘null’ cells) revealed that all subsets 
contain latent virus (Flano et al., 2003).  
MuGHV latency usually is studied in the spleen (Flano et al., 2000; Flano et al., 
2003; Sunil-Chandra et al., 1992).  Latency typically is assessed by measuring the ability 
of cell-associated virus to form lytic plaques in vitro (Flano et al., 2000).  Latency also 
can be estimated by measuring the frequency of cells harboring viral genome through use 
of a limiting-dilution polymerase chain reaction assay. In the absence of lytic virus in the 
host, this assay measures total (that is, ‘genome-positive’) latency (Flano et al., 2003; 
Flano et al., 2002; Weck, Kim, Virgin, & Speck, 1999).  Based on plaque formation, 
limiting-dilution assays can provide a quantification of both preformed infectious virus 
particles as well as cells that reactivate latent MuGHV within the same tissue sample, 
allowing the investigator to distinguish between lytic and latent virus. In contrast, 
polymerase chain reaction-based assays quantify overall amounts of virus in a sample 
without distinguishing between lytic and latent virus (Virgin, Presti, Li, Liu, & Speck, 
1999).  At the beginning of the latent phase, virus is present in 1 in 103 spleen cells at day 
14 after infection, but this titer then declines rapidly, such that viral load at 4 wk after 
infection is barely above the assay limit of detection (about 1 in 106 to 1 in 107 spleen 
cells) of a limiting-dilution polymerase chain reaction assay (Cardin et al., 1996).  The 
development of latency is associated with splenomegaly, polyclonal B cell activation, 
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autoantibody production, and lymphocytosis. The lymphocytosis consists largely of 
CD8+ T cells, a large proportion of which express Vβ4+ T cell receptor (Sunil-Chandra 
et al., 1992).  
The virus is able to maintain its presence in the spleen during latency through an 
open reading frame within the viral genome (ORF 73) that encodes latency-associated 
nuclear antigen. This protein binds to the viral-latency associated origin of replication 
and the host cell chromosome, thereby promoting maintenance of the viral episome 
during latency by partitioning the viral genome to daughter cell DNA during mitosis 
(Moorman, Willer, & Speck, 2003).  Because viral gene expression is highly constrained 
during latency, the virus and its low levels of expressed proteins present a difficult target 
for immune intervention (Nash et al., 1994).  
Viral reactivation. Host immune control normally prevents reactivation of latent 
virus. Both humoral and cellular immune processes contribute to the maintenance of 
latency (Gangappa, Kapadia, Speck, & Virgin, 2002; Kim, Flano, Woodland, & 
Blackman, 2002; Stevenson, 2004; Stewart, Usherwood, Ross, Dyson, & Nash, 1998). 
CD28 is a costimulatory molecule that inhibits humoral immunity and the coordination of 
T and B cell responses (Kim et al., 2002). CD28–/– mice do not form antibodies but 
nonetheless control lytic MuGHV replication; latency is established in CD28–/– mice, but 
depletion of T cells in CD28–/– mice with latent infection allows viral reactivation, as 
indicated by the rapid appearance of lytic virus in both lung and spleen (Kim et al., 
2002).  In contrast, T cell-depletion of infected C57BL/6 mice, which have high levels of 
neutralizing antibodies, does not allow viral reactivation (Kim et al., 2002).  Reactivation 
of both EBV and MuGHV occurs via the initiation of viral replication in latently infected 
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B cells (Cohen, 2000).  
The processes that trigger reactivation of latent virus are largely unknown. 
Signaling through nuclear factor κB is postulated to inhibit reactivation; absence of this 
signaling releases inhibition of replication and allows viral reactivation (Brown et al., 
2003).  Ex vivo exposure of latently infected cells to lipopolysaccharide has been shown 
to induce reactivation (Moser, Upton, Gray, & Speck, 2005) Latent virus undergoes 
apparently random reactivation in some host cells, inducing the production of low levels 
of cytokines (Moser et al., 2005).  This process occurs in macrophages, B cells, and 
dendritic cells after short-duration latency (that is, soon after the lytic phase) and in B 
cells after long-term latency (Flano et al., 2003).  
 
Inflammatory cytokines and behavior in GHV infections  
Patients with EBV infections typically report sore throats and respiratory 
symptoms during the active phase of infection and develop daytime sleepiness and 
fatigue during both active and latent stages (Vollmer-Conna et al., 2004).  Circulating and 
centrally induced cytokines may mediate some of these symptoms. For example, 
administration of exogenous IFNγ causes daytime fatigue in humans, (Spath-Schwalbe, 
Lange, Perras, Fehm, & Born, 2000) and B cells from patients with latent EBV infections 
express IFNγ whereas cells from noninfected people do not (Jabs, Wagner, Schlenke, & 
Kirchner, 2000).  Circulating levels of the proinflammatory cytokines IL1β and IL6 
correlate with the occurrence of symptoms (for example, fever, malaise, pain, fatigue, 
depressed mood, and inability to concentrate) in patients with active EBV infection 
(Vollmer-Conna et al., 2004).  However, relatively little is known about how changes in 
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sleep, core temperature, activity, and other measures of well-being change with respect to 
the host immune response and disease progression. Overall, immune responses in humans 
have not yet been linked strongly to behavior or illness across the time course of active 
and latent phases of EBV infection. However, performing such studies in mice with 
MuGHV infections could provide insights into the pathogenesis of fatigue and other 
sickness behaviors that can be debilitating to humans. 
Although cytokines are normally part of the host mechanisms for controlling the 
virus, they also can promote both the spread of GHV and the survival of infected cells. 
During the lytic phase of EBV infection, the viral envelope component glycoprotein (gp) 
350 is the primary modulator of expression of cytokines and their receptors in the host 
(Jung et al., 2001).  gp350 mediates virus absorption and penetration into host cells via 
the complement receptor CD21 (Jung et al., 2001).  A 1-to-1 interaction between CD21 
and GHV-infected cells is required for adsorption and viral endocytosis and is the 
primary determinant of EBV tissue tropism (Tanner, Weis, Fearon, Whang, & Kieff, 
1987; Tanner, Whang, Sample, Sears, & Kieff, 1988; Urquiza, Lopez, Patino, Rosas, & 
Patarroyo, 2005).  
Binding of gp350 to CD21 induces binding of NFIL6, an encoding nuclear factor 
that in turn induces the expression of IL6, nuclear factor κB, and other factors that 
contribute to IL6 expression (D'Addario, Libermann, Xu, Ahmad, & Menezes, 2001).  
IL6 stimulates proliferation of B cells and thereby promotes spread of the virus by 
generating targets for infection. In addition, IL6 inhibits the killing of virally infected 
cells by natural killer cells (Tanner & Tosato, 1991), further promoting the survival of 
infected cells. Further, gp350 promotes expression of tumor necrosis factor α, IL8, and 
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IL10 in monocytes via nuclear factor κB and related cascades (for example, protein 
kinase C, phosphoinositide 3 kinase, and tyrosine kinases) (D'Addario et al., 2000).  The 
MuGHV homolog of EBV gp350 is gp150, which is crucial for the stimulation of 
cytokine responses (Stewart et al., 1996).  
Cytokines are pivotal in the modulation of both innate and adaptive immunity 
during MuGHV infections; their release at different times of infection is summarized in 
Figure 1. The lytic phase of MuGHV infection is associated with production of IL1α, 
IL2, IL6, and IL10 in the spleen (Sarawar et al., 1996).  IFNγ is vital for clearance of 
virus from the lung via the induction of cytotoxic T cells, natural killer cells, and 
macrophages and controls the latent phase by curtailing reactivation (Dutia, Clarke, 
Allen, & Nash, 1997; Sarawar et al., 1997).  IL6 is present in high concentrations in 
blood during MuGHV infection (Sarawar et al., 1996).  IL10 also influences MuGHV 
pathogenesis. For example, IL-10 knockout mice show reduced viral load in the spleen 
yet increased splenomegaly (Peacock et al., 2001).  
The relationships of cytokines to the development of sickness behaviors (for 
example, anorexia, fever, fatigue, behavioral depression, hyperalgesia, sleep changes) in 
mice have not yet been documented for MuGHV infection. Although the immune 
responses induced by EBV and MuGHV infections have many similarities (Flano et al., 
2002), little is known about virus-induced behavioral changes under either condition. 
Studies on EBV and behavior are complicated by uncertainties regarding the dose of 
virus received, and the time course of disease development and regression may vary due 
to environment or genetics of the patient. Therefore, not only is MuGHV a good model 
for studying interactions between GHV infection and host immune responses, but it may 
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also be useful as a well-controlled model for studying interactions between immune 
responses and behavioral symptoms. 
 
Other considerations relevant to MuGHV 
The strain of mice used can be an important consideration in the study of MuGHV 
infections. For example, BALB/c mice show greater induction of chemokines and greater 
viral gene expression during the lytic phase of the infection than do C57BL/6 mice; 
infected BALB/c mice also have higher levels of IFNγ in lung (Weinberg, Lutzke, 
Alfinito, & Rochford, 2004).  The greater chemokine production by BALB/c mice could 
promote recruitment of leukocyte target cells to the lungs, thereby augmenting viral 
replication and increasing susceptibility to infection in these mice. However, the latent 
viral load in spleen was similar in both strains at 15 d after inoculation, suggesting that 
the establishment of latency was similar in the 2 strains (Weinberg et al., 2004). These 
strain differences are likely to be caused by genetic and inherent immune response 
differences in these mouse strains, such as the differences in IFNγ protein response. 
Both the route of administration and the dose of virus used to inoculate mice with 
MuGHV vary across studies. However, the frequency of in vitro reactivation in 
splenocytes was the same across a 107-fold range of doses administered via 
intraperitoneal injection and across a 104-fold range of doses administered via intranasal 
administration (Tibbetts et al., 2003b).  These findings suggest that the establishment of 
latency is relatively independent of both the route of administration and infectious dose 
and that latent infection can be established with extremely low doses of virus. 
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Differences between MuGHV and EBV 
MuGHV and EBV differ in terms of their subgroups, tendency to induce 
lymphoma, and the nature of CD8+ T cell expansion. Due to genomic organization, EBV 
is classified as a gamma-1-herpesvirus, or a lymphocryptovirus, whereas MuGHV is 
classified as a gamma-2-herpesvirus, or a rhadinovirus. More specifically, the MuGHV 
genome lacks homologs of EBV latency-associated and transforming proteins. 
Rhadinoviruses also differ from lymphocryptoviruses in their ability to infect both B and 
T cells (Simas & Efstathiou, 1998).  Furthermore, EBV is well-known to cause 
lymphomas, whereas lymphomas occur only in a low percentage of MuGHV-infected 
mice, and lymphomas from infected mice contain few MuGHV-infected cells (Sunil-
Chandra et al., 1992).  MuGHV and EBV also differ in the nature of expanded T cell 
populations.  In EBV infections, CD8+T cells are activated during the acute response to 
lytic epitopes and are Vβ-specific (Sutkowski, Conrad, Thorley-Lawson, & Huber, 2001).  
In contrast, the response to MuGHV is unrestricted with regard to major 
histocompatibility complex haplotype and is not specific for viral epitopes (Flano et al., 
2002).  
Conclusions 
Although MuGHV and EBV differ in several ways, their similarities outweigh 
their differences and create an opportunity for use of MuGHV as an in vivo model of 
EBV and other GHVs that elicit debilitating behavioral symptoms such as chronic fatigue 
and sleep problems. Like EBV, MuGHV causes a life-long infection that is associated 
with various disease conditions. Both viruses impede host immune processes and evade 
immune surveillance. Because of numerous impediments and limitations to human GHV 
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research, the availability of this in vivo murine GHV infection will facilitate elucidation 
of mechanisms that underlie and link virus reactivation, cytokine release, and clinical 
symptoms such as chronic fatigue. MuGHV offers an effective in vivo tool for 
surmounting the hurdles inherent in human GHV research and provides an excellent 
model to study the behavioral effects in response to immune challenge by GHVs, such as 
EBV.  
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Table 2.1 Partial list of mammalian gammaherpesviruses (limited list) 
 




Herpesvirus saimiri (HVS) 
 
Epstein-Barr virus (HHV4) Kaposi sarcoma-associated herpesvirus 
 (KSHV or HHV8) 
 
Herpesvirus papio (of baboons) Rhesus monkey rhadinovirus (RRV) 
 Equine herpesvirus 2 
 Murine herpesvirus 68  
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Figure 2.1.  Schematic representation of infection with gammaherpesvirus and various 
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EFFECTS OF INFECTION WITH MURINE GAMMAHERPESVIRUS ON 




INTRODUCTION: Human gammaherpesvirus (GHV) infections, such as with 
Epstein Barr Virus (EBV) are associated with chronic fatigue.  Immune responses to 
EBV include elevated concentrations of cytokines known to regulate sleep and induce 
fatigue.  Murine GHV-68 (MuGHV) has been used as a mouse model of effects of EBV 
infection on immune function.  However, the impact of infection with MuGHV on 
behavior of mice has never been studied.  We hypothesized that MuGHV infection 
induces fatigue and alter sleep of mice.  Furthermore, we hypothesized that chronic 
infection with MuGHV exacerbates responses to subsequent challenge.   
METHODS: Mice were maintained on a 12:12 h light:dark cycle at 29 °C.  
Animals were surgically implanted under isoflurane anesthesia with transmitters to record 
core body temperature, activity, and the EEG and were housed in cages containing a 
running wheel and infrared detector.  Mice were administered vehicle intranasally (i.n.) at 
dark onset and control recordings were made for 4 days.  Mice were then inoculated i.n. 
at dark onset with 400 PFU (n=13) or 40,000 PFU (n=8) of MuGHV and recordings 
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made for 30 days post-inoculation.  After this 30 day period, they were injected 
interperitoneally (i.p.) at dark onset with vehicle and 24 h of control recordings.  After 
this control period, they were then subjected to a secondary immune challenge in the 
form of an IP injection of 10 μg lipopolysaccharide (LPS).  Recordings continued for 5 
days.   
RESULTS: Infection of mice with MuGHV decreased wheel running, core body 
temperature, food intake and body weight in dose-specific patterns.  Although sleep of 
mice inoculated with 400 PFU MuGHV was not altered, mice inoculated with 40,000 
PFU MuGHV spent more time in NREM sleep and less time in wakefulness, changes that 
coincided with the peak of active viral replication.  The impact of secondary immune 
challenge with LPS on sleep and body temperature differed with dose of inoculation, with 
the major effect being one of prolonged duration of hypothermia and increases in NREM 
sleep in viral-inoculated mice.   
CONCLUSIONS: These results indicate that mice infected with MuGHV become 
fatigued as evidenced by reductions in activity.  In addition, sleep is altered and there are 
long-term effects on thermoregulatory mechanisms.  These results also suggest that the 
ability of the immune system to respond normally to subsequent challenge is 
compromised in mice infected with MuGHV. Overall, these studies suggest infection of 
mice with MuGHV may be a useful model for facets of post-viral chronic fatigue.   
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Introduction 
Chronic fatigue is a widespread, disabling symptom that decreases quality of life 
and productivity in the workplace (Bombardier & Buchwald, 1996).  Chronic fatigue 
syndrome (CFS) is difficult to study in humans due to the heterogeneous patient 
population and the variety of triggering events (Afari & Buchwald, 2003; Evans, 1991; 
Krupp, Mendelson, & Friedman, 1991; Kyle & DeShazo, 1992).  Although the etiology 
of CFS remains elusive, many patients develop symptoms similar to CFS after infection 
with Epstein-Barr virus (EBV), a gammaherpesvirus (GHV).  Numerous studies suggest 
EBV infection may be central to the pathogenesis of CFS and may perpetuate the chronic 
state of fatigue (Glaser & Kiecolt-Glaser, 1998; Jones, 1988; Natelson et al., 1994).  The 
hypothesis that infection with EBV is a triggering event for CFS derives, in part, from 
observations that individuals with CFS have higher antibody titers to EBV (Glaser et al., 
2005; Matthews, Lane, & Manu, 1991; Swanink et al., 1995).    CFS patients also 
respond abnormally to secondary immune challenge of lipopolysaccharide (LPS), 
suggesting abnormal immune responses to subsequent infection (Gaab, et al., 2005).  
EBV is a ubiquitous human GHV that establishes life-long latency in the host.  EBV and 
other GHVs have two distinct phases, an active infectious phase, and a latent phase 
(Flano, Woodland, & Blackman, 2002a).  GHVs are able to survive for the lifetime of the 
host because they have evolved complex mechanisms to evade detection by the host 
immune system.  Transmission of EBV can occur through blood products, 
transplantation, saliva, and sexual activity (Mandell, Bennett, & Dolin, 1995), which 
makes prevention of the spread of this virus extremely challenging.  Data indicate that 
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95% of all adults have antibodies against EBV (Rickinson & Kieff, 2001; Mandell et al., 
1995), yet only a small fraction of adults develop CFS.   
Cytokines may play a role in the pathophysiology of CFS because patients have 
elevated concentrations of interleukin (IL)-1, IL-6 and interferon (IFN)-γ (Hornef, 
Wagner, Kruse, & Kirchner, 1995).  These aforementioned cytokines are implicated in 
the regulation of multiple central nervous system processes, among them sleep and 
thermoregulation.  Many individuals infected with EBV and CFS patients report 
nighttime sleep disturbances as well as daytime fatigue (Unger et al., 2004).  CFS 
patients report a high incidence of low-grade fevers, possibly due to alterations in 
thermoregulatory mechanisms (Fukuda et al., 1994).   However objective studies of 
fatigue, sleep disturbances and temperature alterations in humans have not been widely 
done due to the difficulty in studying EBV and CFS. 
 A mouse GHV, MuGHV-68, has been identified that shares many similarities 
with human EBV (Flano, Woodland, & Blackman, 2002b).  Both viruses have an 
infectious active phase in the lung and establish latency in the spleen.  MuGHV is a 
reliable model for EBV pathogenesis because it is a herpesvirus that has the same route 
of infection, elicits the same innate and adaptive immune responses, and has similar DNA 
structure [reviewed (Olivadoti, Toth, Weinberg, & Opp, 2007)].  In addition, MuGHV 
does not normally cause mortality in mice, which allows assessment of chronic effects of 
long-term viral infection.  In this study we leverage these features of chronic infection 
with MuGHV-68 to determine the impact of chronic viral infection on sleep-wake 
behavior, activity and temperature patterns of C57BL/6J mice.  We hypothesize that 
infection with MuGHV alters activity patterns, sleep, and core body temperature in a 
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manner that resembles facets of human responses to EBV.  Furthermore, we hypothesize 
that the impact of chronic infection on these behaviors and processes depends upon the 
magnitude of viral load during infection.  We also predict that responses to secondary 
immune challenge of chronically infected mice are exacerbated.  We now report that the 
magnitude of alterations of sleep and activity patterns, body temperature and responses to 




Adult male C57BL/6J mice (22 – 30 g at time of surgery; the Jackson Laboratory, 
Bar Harbor, ME) were individually housed in microisolator cages and maintained on a 
12:12 h light:dark cycle at an ambient temperature of 29 ± 1 ºC.  Water and rodent chow 
(Lab Diet 5001, PMI Nutrition International, Brentwood, MO) were provided ad libitum.  
Food was recorded daily.  All procedures were approved by the University of Michigan 
Committee on Care and Use of Animals in accordance with the US Department of 
Agriculture Animal Welfare Act and the National Institutes of Health policy on Humane 
Care and Use of Laboratory Animals. 
 
Surgical Procedure 
Under isoflurane anesthesia (4% induction, 2% maintenance), a battery-operated 
telemeter [model # ETA10-F20, Data Sciences International (DSI), St. Paul, MN] was 
surgically implanted into the peritoneal cavity.  Insulated biopotential leads from the 
transmitter were subcutaneously routed to the skull.  The biopotential lead wires were 
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then attached to two small stainless steel screws (#80 x 1/8 in., Small Parts, Miami Lakes, 
FL), which were implanted in the skull over the frontal and parietal brain cortices and 
served as electroencephalographic (EEG) recording electrodes.  After surgery the mouse 
was placed on a heating pad at 37 ºC until it recovered from anesthesia and was 
ambulatory.  Ibuprofen (0.2 mg/mL) was provided in the drinking water as an analgesia 
beginning 24 h before surgery and continuing for 48 h after surgery (Hays, et al., 2000).  
A broad-spectrum antibiotic (imipenem, 25 mg/kg subcutaneous) and an injectable 
analgesic (buprenex, 0.05 mg/kg) were given immediately after surgery.  Mice were 
allowed 21 days to recover from surgery before experiments began.  Mice were housed in 
the recording room during the recovery period to habituate to the recording environment.   
 
Recording Apparatus 
The signal emitted by the transmitter was detected by a receiver (RPC-1, DSI) 
located under each mouse’s cage.    The signal was then fed to a DSI analog converter 
(ART Analog-8 CM) and frequency signals converted into EEG and temperature voltages 
using calibration factors provided by DSI that were specific for each transmitter.  The 
output from the DSI analog converter was then captured by an A/D board (model PCI-
3033E, National Instruments, Austin, TX), which digitized the data at 128 HZz with 16-
bit precision.  The voltage values obtained from the temperature channel of the 
transmitter were converted to engineering units (°C) by regression using coefficients 
specific for each transmitter and obtained by calibration with a water bath.  This 
commercially available telemetry system has previously been used to determine sleep-
wake behavior of mice (Tang & Sanford, 2002; Morrow & Opp, 2005a; Morrow & Opp, 
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2005b), and temperature and activity patterns from other small mammals (Herold, Spray, 
Horn, & Henriksen, 1998).  Cage activity was detected using an infrared sensor housed in 
an observation unit that also contained a camera (BioBserve, GmbH, Bonn, Germany).  
Thus, mice could be observed during both the light and dark period of the light:dark 
cycle.  Movements detected by the infrared sensor were converted to a voltage output, the 
magnitude of which was directly related to the magnitude of movements detected.  Wheel 
running was determined by detecting TTL pulses triggered by a switch on the axel of the 
wheel.  All signals (EEG, body temperature, wheel running and cage activity) were stored 
as binary files until further processing.   
During acquisition, the EEG was digitally filtered using Chebyschev filters with 
3rd order coefficients into frequency bands as follows:  delta, 0.5 to 4.0 Hz; theta, 6.0 to 
9.0 Hz; alpha, 12 to 16 Hz.  These filtered EEG signals were integrated over 1-s periods, 
and stored as part of the binary file structure.  Arousal state designations were made with 
10-s resolution on the basis of visual inspection of the recordings using custom software 
(ICELUS, M. Opp, University of Michigan) written in LabView for Windows (National 
Instruments).  Determination of arousal state was made on the basis of EEG, body 
movements, and integrated delta and theta frequency values.  Each state was classified as 
wakefulness, NREM sleep, or REM sleep.  Wakefulness was defined on the basis of a 
low amplitude, mixed frequency (delta ≅ theta) EEG accompanied by body movements.  
Increases in body temperature during wakefulness are associated with activity.  NREM 
sleep was identified by increased absolute EEG amplitude, integrated values for the delta 
frequency band greater than those for theta, and lack of body movements.  Body 
temperature declines upon entry into NREM sleep until it reaches a regulated asymptote.  
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REM sleep was characterized by a low amplitude EEG, with integrated values for the 
delta frequency band less than those for the theta frequency band.  Epochs containing 
either movement artifacts or electrical noise were tagged and excluded from subsequent 
spectral analyses.  The raw, non-integrated EEG signals were also processed using fast 
fourier transforms (FFT) to yield power spectra between 0.5 and 40 Hz in 0.5 Hz 
frequency bins.  These spectra were computed from the five consecutive 2-s EEG 
segments comprising the 10-s epoch.  These five spectra were averaged to produce one 
spectra for the epoch, which was matched to state to provide state-specific power spectra.  
Measures of sleep consolidation / fragmentation were made based upon determination of 
the number of transitions from one arousal state to the next.   
 
Experimental Protocols 
Viral Preparation and Inoculation Procedure 
Viral stock of MuGHV-68 (8.2 x 105 PFU/mL, Blackman Lab, Trudeau Institute) 
was stored at -80º C and thawed just prior to use.  To achieve a 400 PFU dose the stock 
was diluted to by adding 170 μL of viral stock to 10 mL of Hank’s Balanced Salt 
Solution (HBSS).   50 μL of straight stock was used to inoculate mice in the 40,000 PFU 
dose group. Mice were lightly anesthetized with isoflurane and held upright by the scruff 
of the neck while 30 – 50 μl of fluid were placed into the nostrils (i.n.) with a 
micropipette.  Approximately half of the liquid was injected into each nostril and mice 
were observed until waking from the anesthesia. 
 
Experiment I: Impact of MuGHV infection on sleep, activity and body temperature. 
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After recovery from surgery, mice were placed in microisolator cages equipped 
with running wheels and were given two weeks for adaptation to use of the wheel.  After 
adaptation, mice were inoculated at dark onset with vehicle (HBSS) (30 μL for 400 PFU, 
50 μL for 40,000 PFU).  After i.n. administration of vehicle, control recordings of EEG, 
core body temperature, wheel running and cage activity were obtained for four 
consecutive days (see Figure 3.1).  After control recordings, mice were inoculated at dark 
onset with either 30 μl vehicle containing 400 PFU of MuGHV (n=13) or with 50 μl 
vehicle containing 40,000 PFU (n=8) of MuGHV.  Recordings continued for 30 
consecutive days after MuGHV inoculation.  Husbandry was done on day 12 after viral 
inoculation, and mice were weighed daily.  To determine daily food consumption, pre-
weighed portions of mouse chow were placed in the cage each day and uneaten chow was 
removed and weighed.  After inoculation of mice with MuGHV all activities were 
conducted under Biohazard Safety Level 2 conditions. 
 
Experiment II:  Lipopolysaccharide (LPS)-induced alterations in sleep, activity and body 
temperature of chronically infected mice. 
On day 34 post-inoculation, infected animals were given intraperitoneal (i.p.) 
injection of 0.2 mL pyrogen-free saline (vehicle) and recordings obtained for 24 h.  
Infected mice were subsequently injected i.p. with10 μg of LPS (Escherichia coli 
serotype O111:B4; Sigma-Aldrich, St. Louis, MO) and recordings continued for 5 days. 
 
Experiment III: Determination of viral load during infection with MuGHV. 
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Mice were kept in the same conditions as above and inoculated with either vehicle 
or with 40,000 PFU of MuGHV.  Mice were sacrificed four days after vehicle 
administration (n=8), or 5 days (n=6), 9 days (n=6) or 26 days (n=8) after inoculation 
with MuGHV.  Lung and spleen were removed and flash-frozen in liquid nitrogen and 
stored at -80 °C.  DNA extracted from frozen tissue samples (DNeasy Kits, Qiagen, 
Valencia, CA) was used to determine viral load by quantitative PCR (Hulse, Kunkler, 
Fedynyshyn, & Kraig, 2004).  Viral load was quantified in spleen and lung of infected 
mice by real-time PCR using the ABI Prism 7700Sequence Detector (PE Applied 
Biosystems) to detect a 70bp region of the MuGHV-68 gB gene: forward 5’-
GGCCCAAATTCAATTTGCCT-3’; reverse 5’-CCCTGGACAACTCCTCAAGC-3’; 
probe (5’) 6-(FAM)-ACAAGCTGACCACCAGCGTCAACAAC-(TAMRA)(3’) where 
FAM is a reporter dye and TAMRA is a quencher dye. Standard curves were generated 
using known amounts of plasmid containing gB PCR fragment.  The DNA copy number 
was calculated from the molecular weight of the DNA construct of Avogadro’s number.  
One hundred nanograms of DNA extracted from each mouse spleen was used per 
reaction (Weinberg, et al., 2004).   
 
Statistical Analyses 
Statistical analyses were performed using SPSS v. 13.0 for Windows.  Data were 
evaluated in 6 and 12 h time blocks using linear mixed models analysis with a Bonferroni 
correction.  The amount of time spent in vigilance states, core body temperature, wheel 
running, cage activity, transitions from one state to another, and delta power during 
NREM sleep were the dependent variables and manipulation (vehicle, MuGHV) was the 
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independent variable.  An alpha level of p< 0.05 was accepted for all statistical tests as 
indicating significant departures from control values. 
 
Results 
Experiment I: Impact of MuGHV infection on sleep, activity and body temperature. 
Activity 
Wheel running activity of mice inoculated with 400 PFU MuGHV progressively 
declined in the late portion of the dark phase (hours 7 – 12, p < 0.05, Figure 3.2) during 
days 14 – 30 post-inoculation.   Wheel running of these mice also decreased during the 
late portion of the light period throughout the entire course of the infection compared to 
vehicle control (p<0.05 Figure 3.2).  Wheel running of mice inoculated with 40,000 PFU 
of MuGHV was decreased during both dark and light phases throughout the entire 
recording period (p<0.01 dark period, p<0.001 light period, Figure 3.2).  General cage 
activity of mice inoculated with either the 400 PFU or 40,000 PFU dose of MuGHV was 
not altered at any time throughout the recording protocol (data not shown). 
 
Food intake and body weights 
Food intake decreased significantly during days 8 – 10 (p<0.05), and body weight 
dropped during days 7 – 14 after inoculation with 40,000 PFU of MuGHV (p<0.05, 
Figure 3.4).    Food intake and body weights of mice were not altered after inoculation 




Mice inoculated with 400 PFU MuGHV responded with hypothermia that 
progressed throughout the course of infection and deviated statistically between post-
inoculation at various time points throughout the recording period (Figure 3.3).  The 
largest drops in body temperature occurred during the second half of the dark period 
[hours 7 – 12 (post-inoculation days 14 – 30, p<0.05, Figure 3.3)], and the second half of 
the light period [hours 13 – 18 (post-inoculation days 14 – 20, p<0.05, Figure 3.3)], Mice 
inoculated with 40,000 PFU had a significant hypothermia on day 9 post-infection 
compared to vehicle (p<0.01 Figure 3.2) during the late portion of the dark period. 
 
Sleep-wake behavior 
Visual scoring of 24 h records from days 1, 3, 5, 7, 9, 24, 26, 28, and 30 post-
inoculation was completed for mice inoculated with 400 PFU, and scoring was completed 
on days 3,5,7-14, and 26 for mice inoculated with 40,000 PFU.  Scoring results from 
mice infected with 400 PFU indicated that sleep-wake behavior of mice was not altered 
(data not shown).  In contrast, sleep-wake behavior of mice inoculated with 40,000 PFU 
of MuGHV was altered for prolonged periods.  On day 7 after inoculation NREM sleep 
was decreased, however between days 8 – 11 post-inoculation with this dose of MuGHV, 
NREM sleep was increased (p < 0.001; Figure 3.6).  The increase in NREM sleep 
occurred primarily during the dark period of days 8-11.  Effects of 40,000 PFU of 
MuGHV on REM sleep were apparent during the dark periods of days 8, 9 and 10 post-
inoculation with decreases in NREM sleep on these days after inoculation (P<0.05; 
Figure 3.6).  Sleep of mice infected with 40,000 PFU of MuGHV was fragmented during 
the light period of day 7 and during the dark period of days 8 and 9 (p<0.05), as 
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evidenced by significant increases in the number of transitions from one state to another.  
Significant decreases in wakefulness during the dark period of day 9 were also observed 
(p<0.05).  Sleep-wake behavior on days 5 and 26 after inoculation with 40,000 MuGHV 
was not altered (Figure 3.6).  Delta power during NREM sleep did not significantly 
change after inoculation with either dose of MuGHV (data not shown).     
 
Experiment II:  LPS-induced alterations in sleep, activity and body temperature of 
chronically infected mice. 
Food intake and body weight 
There were no significant differences in food intake or body weights of mice 
inoculated with 400 PFU of MuGHV and subsequently challenged with LPS compared to 
vehicle control.  Although food intake of mice inoculated with 40,000 PFU of MuGHV 
decreased during day 4 after LPS administration (p<0.05), drops in body weight achieved 
statistical significance only during the first two days after LPS administration (data not 
shown, p<0.01).  The impact of LPS on food intake and body weights of mice inoculated 
with MuGHV differed depending on the dose of viral inoculation; food intake on day 3 
and body weights on days 1 and 3 post-LPS administration of mice inoculated with 
40,000 PFU of MuGHV were significantly less than those of mice inoculated with 400 
PFU of MuGHV (data not shown).  
 
Body temperature 
Uninfected C57BL/6J mice injected i.p. with LPS developed hypothermia that 
lasted for 7 hours (p=0.01, Figure 3.7).  This period of hypothermia was followed by 
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fever during the subsequent light period, 12 h after LPS injection  (p<0.001).  These 
results are from previously published data (Morrow, Opp, 2005) that has been re-
analyzed.  Hours 24-48 after LPS were newly analyzed from this previously published 
data set.  Hypothermic responses to LPS of mice inoculated with 400 PFU of MuGHV 
were prolonged (Figure 3.8); these animals were hypothermic during the dark periods of 
days 1 and 2 post-inoculation (hours 1- 12 and 24 – 36, p<0.01, nadir magnitude of -2.2 ± 
0.6 ºC).  The hypothermic response to LPS in these animals was still apparent during the 
late portion of the dark periods of days 3 – 5 (data not shown).  Similar to uninfected 
C57BL/6J mice, the temperature responses of mice inoculated with 40,000 PFU of 
MuGHV to LPS consisted of an initial 6-h febrile response (peak magnitude of 1.3 ± 0.5 
ºC)  followed by a hypothermic response that lasted 12 h (nadir magnitude of -1.78 ± 
0.25 ºC, Figure 3.9).   However, in contrast to uninfected C57BL/6J mice and similar to 
mice inoculated with 400 PFU of MuGHV (Figure 3.8), mice inoculated with 40,000 
PFU of MuGHV exhibited hypothermic responses during the second and third dark 
periods (hours 24 – 36 and 48 – 60) post-injection (Figure 3.9).  The hypothermic 
responses of mice inoculated with either 400 PFU or with 40,000 PFU of MuGHV were 
of greater magnitude, and of longer duration than observed in uninfected C57BL/6J mice. 
 
Sleep-wake behavior 
Injection of LPS at dark onset into uninfected C57BL/6J mice increased NREM 
sleep and suppressed REM sleep during post-injection hours 1 – 12 (Figure 3.7).  
However, unlike responses of uninfected mice, the LPS-induced increase in NREM sleep 
of C57BL/6J mice inoculated with 400 PFU of MuGHV was prolonged and apparent 
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during post-injection hours 1 – 12 and during the subsequent dark period (post-injection 
24 – 36) (p<0.05, Figure 3.8).  After this period during which NREM sleep was 
increased, NREM sleep of mice inoculated with 400 PFU of MuGHV and injected with 
LPS was reduced during the light periods of days 3 – 5 post-injection (data not shown).  
REM sleep of these animals was reduced during most of the light periods on post-
injection days 3 – 5 (p< 0.05, Figure 3.8). Sleep of mice inoculated with 400 PFU of 
MuGHV and then injected with LPS was fragmented for 36 hours post-injection 
(p<0.001, Figure 3.8) as well as during the light period of days 3, 4 and 5 (data not 
shown).  Amount of time mice inoculated with 400 PFU of MuGHV spent awake 
mirrored increases in NREM sleep, being reduced during the first 12 h after LPS 
injection (p<0.01) and increased during most portions of the light period on post-injection 
days 3 – 5 (p<0.001, Figure 3.8).  NREM sleep of mice inoculated with 40,000 PFU of 
MuGHV was increased hours 1 – 12 and 24 – 30 post LPS injection (p < 0.001), whereas 
REM sleep was reduced during post-injection hours 12 – 18 and 24 – 32 (p < 0.001, 
Figure 3.9).  Sleep of these mice was fragmented during the first 18 h after LPS (p < 
0.001, Figure 3.9).  Delta power during NREM sleep of mice inoculated with 400 PFU 
was decreased during the light period 12 hours after LPS injection whereas delta power 
during NREM sleep of mice inoculated with 40,000 PFU MuGHV was not significantly 
altered (Figure 3.9). 
MuGHV infection had differential impact on LPS-induced alterations in sleep-
wake behavior of mice depending on the dose used (Figure 3.10).  NREM sleep during 
the 12 h dark period after injection of LPS of mice inoculated with either 400 PFU or 
with 40,000 PFU was more fragmented than NREM sleep of uninfected C57BL/6J mice 
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during comparable periods (p<0.05).  In addition, the effect of LPS on REM sleep of 
mice inoculated with MuGHV differed from that of uninfected C57BL/6J mice.  REM 
sleep of mice inoculated with 400 PFU of MuGHV was not altered by LPS, whereas 
REM sleep of mice inoculated with 40,000 PFU of MuGHV was suppressed by LPS 
injection at dark onset during the subsequent light period, postinjection hours 13 – 24 
(p<0.05).  Delta power during NREM sleep of mice inoculated with 400 PFU of MuGHV 
and then injected with LPS was reduced to a greater extent during postinjection hours 13 
– 18 than that observed in mice inoculated with 40,000 PFU of MuGHV (p<0.05).     
 
Experiment III: Determination of viral load during infection with MuGHV. 
Viral DNA was detected in the lungs and spleens of mice inoculated with 
MuGHV (Figure 3.11).   Viral DNA was not detected in control mice.  Lung viral load 
was highest at 5 days post-infection and almost absent on day 26 after both doses of 
infection.  In the spleen, viral load peaked on day 9 post-inoculation and remained 
detectable at days 26 after inoculation.  
 
Discussion 
 Our results demonstrate that mice become progressively fatigued 
throughout the course of chronic viral infection.  The temporal characteristics of altered 
activity, sleep-wake behavior and thermoregulation coincide with transitions from active 
infection to latency.  Furthermore, the magnitude of these changes in complex behavior is 
dependent upon the dose of virus in the inoculant, i.e., presumed viral load.  Of particular 
interest, fatigue in these mice, as operationally defined as a reduction in activity, is 
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limited to voluntary activity (wheel running) and not obligatory activity (general cage 
activity associated with feeding, drinking, grooming, etc.).  These results are reminiscent 
of the diagnostic criteria of CFS in humans; voluntary activities are curtailed while 
essential activities such as working or taking care of a family are largely maintained 
(Rakib et al., 2005).    Patients suffering from CFS due to different etiologies also differ 
in the extent of their immune perturbations; patients in which CFS onset occurred after an 
infection have more extensive alterations in immune function than normal controls 
(Racciatti, Vecchiet, Ceccomancini, Ricci, & Pizzigallo, 2001).   
 Gammaherpesviruses (GHV’s), such as Epstein-Barr virus (EBV), have been 
linked to the pathology of CFS (Glaser et al., 2005).  Whole blood cultures from 
individuals infected with EBV have abnormal responses to LPS stimulation compared to 
EBV-negative individuals, with increased stimulated concentrations of IL-1, TNF-a and 
IL- 6, and similar findings have been found in patients with CFS as well (Hornef et al., 
1995).   
Although there is much that can be learned from in vitro studies of whole blood 
cultures from individuals infected with EBV or suffering from CFS, there are limitations 
to these types of studies.  Foremost among these limitations is the inability to directly 
relate findings obtained by these in vitro methods to the impact of chronic infection on 
daily life.  It is difficult to study EBV infection, post-viral chronic fatigue, and effects of 
subsequent immune challenge in humans due to the heterogeneity of the patient 
population (age, stage of infection, variable gene expression during latency, 
unpredictability of fatigue trigger, and the time of infection), and subject sampling 
methods (Glaser et al., 2005).  In addition, ratings of fatigue are assessed through self-
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report, which introduces a large component of subjectivity into the results (Hossain et al., 
2005).  Most mechanistic studies have emphasized immune responses, and not the 
relationships between immune responses and behavior.  Moghaddam et al., (1997) 
proposed using a lymphocryptovirus in rhesus monkeys, that elicits similar 
immunological responses, as an immunological model of EBV, however this model is 
neither economical nor practical for laboratory use, and also does not measure behavioral 
responses during infection.  MuGHV is a model for human infection with EBV that 
shares structural and biological properties with EBV, infects mice by the same route as 
EBV in humans, and elicits a similar innate and adaptive immune responses [reviewed in 
(Olivadoti et al., 2007; Flano et al., 2002b)].  In addition, because MuGHV does not 
normally cause mortality in mice, it is possible to assess the impact of chronic long-term 
viral infection.  The MuGHV model of EBV infection has been widely used to determine 
the impact of chronic infection with this virus on immune function.  We extend this 
model to include effects of chronic infection with this virus on CNS function.  Activity 
patterns, sleep-wake behavior, and thermoregulation are altered in mice throughout the 
course of infection with MuGHV in a manner that mimics aspects of EBV infection on 
daytime activity and nighttime sleep of humans. 
Many patients with CFS or individuals infected with EBV report disrupted 
nighttime sleep, including problems of sleep maintenance (Rakib et al., 2005; Fossey et 
al., 2004).  Sleep-wake behavior of mice inoculated with MuGHV is altered.  The most 
dramatic alterations in sleep-wake behavior are the increases in NREM sleep and 
reductions in REM sleep that occur at times that parallel peak viral replication in the lung 
(Flano, Kim, Moore, Woodland, & Blackman, 2003).  In addition, sleep of mice 
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inoculated with MuGHV is fragmented during these periods of altered behavior.  These 
alterations in sleep of mice inoculated with MuGHV, in some respects, mimic the 
disruptions to nighttime sleep often reported in patients with CFS or EBV infection.  
Because the disruptions in sleep of infected mice are most apparent during peak of active 
infection in the lung, these results also suggest that virus-induced alterations in arousal 
state are specific to the peak of active infection. 
Immune function of patients with CFS has been widely investigated.  Although 
results vary between studies, common findings include impairment of  cell-mediated 
immunity (Klimas, Salvato, Morgan, & Fletcher, 1990; Siegel et al., 2006), chronic 
immune activation [reviewed in (Devanur & Kerr, 2006)], and elevated concentrations of 
cytokines (Cannon et al., 1999).  In addition, many in vitro studies demonstrate that 
immune responses of samples from CFS patients differ from those of healthy controls in 
many aspects.  For example, Visser et al. (Visser et al., 2001) report significant 
differences in cytokine production in response to LPS stimulation of whole blood cultures 
from CFS patients.  LPS stimulation of whole blood cultures from CFS patients also 
results in increased IgM and IgA (Hornef, et al. 1995; Maes, Mihaylova, & Leunis, 
2007), and stimulated production of cytokines such as IL-6 and TNF-α that correlate to 
fatigue ratings in these subjects (Gaab et al., 2005).   
Changes in sleep-wake behavior during infection with MuGHV may be mediated 
by virus-induced alterations in concentrations and/or profiles of cytokine either in brain 
or in the periphery.  We hypothesize that increased NREM sleep during days 7 – 14 post-
inoculation may be driven, in part, by elevated concentrations of IL-1, TNF-α, and/or IL-
6.  IL-1β and TNF-α are involved in the regulation of normal, spontaneous sleep in the 
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absence of pathophysiology (Opp, 2005).  It is hypothesized that the alterations in sleep 
in response to immune challenge are due to amplification of these normal physiological 
processes (Krueger et al., 1994).  Body weight and food intake are also significantly 
altered by a higher dose of viral infection, and these changes coincided with previous 
reports of peak viral replication in the lung (Flano, et al., 2002).  Long-term hypothermia 
in infected mice was not completely explained by decreases in activity, which signifies 
that MuGHV affects thermoregulatory mechanisms.  Changes in thermoregulatory 
mechanisms are also noted in patients with EBV and CFS, however the functional 
significance of hypothermia in mice is largely debated, and thus can only be compared 
hesitantly to humans.   
These results also demonstrate the relative response to infection in behaviors that 
are expressed according to either the stage of the virus or the presence of chronic viral 
infection itself, suggesting more than one mechanism of these responses is at work in 
changing specific behavioral reactions to infection.  Understanding how these behaviors 
coincide with initial contraction and course of infection is important in understanding the 
human EBV infection in concordance with immunological parameters.   
Our results also demonstrate abnormal responses of infected mice to secondary 
immune challenge, reflected in sleep and temperature measures that suggest changes in 
the immune system of chronically infected mice, potentially due to latent infection.  In 
addition, the initial dose of virus has an effect on results of secondary immune challenge, 
suggesting that there are both short-term changes, such as changes in activity, sleep and 
temperature, as well as long-term immune changes from infection that are dose-specific.   
Conclusions 
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Previous studies have shown differences in immune reaction to MuGHV in 
different strains of mice (Weinberg, Lutzke, Alfinito, & Rochford, 2004), thus more 
studies are needed to understand the impact of genetic variation on resulting behaviors 
due to infection.  Additional studies can also help explain the impact of physical or 
psychological stress on behavioral responses to viral infection to more accurately 
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Figure 3.1:  Graphic depiction of the timeline used for the protocol in this study.  Mice 
(n=21 total) were implanted with a telemeter and recovered for 21 days.  A two-week 
period was allotted for habituation to the presence of a running wheel.  Mice were then 
given 30 – 50 μl vehicle intranasally with (Hank’s Balanced Salt Solution, HBSS) and 
recordings were made for 4 days.  Mice were then inoculated with either 400 PFU or 
40,000 PFU MuGHV and recordings continued for 30 days.  On day 34 post MuGHV 
inoculation, mice were injected intraperitoneally with pyrogen-free saline (PFS) and 24 h 
control recordings were made.  Then mice were injected IP with 10 μg of 









































































Figure 3.2: Changes in wheel running and core body temperature of mice inoculated with 
either 400 PFU (n=13, open circles) or with 40,000 PFU (n=8, closed circles) of 
MuGHV.  Values are percent change (wheel running) or degrees difference (temperature) 
from values obtained after administration of vehicle, represented by the zero line.  Error 
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Figure 3.3:  Impact of infection with 400 PFU MuGHV on core body temperature in 
C57BL/6J mice.  Values are changes from vehicle (zero line) ± SEM in temperature of 
infected mice (n=13) over 6 hour periods.  Asterisks (*) indicate significant changes from 
vehicle.  Infected mice had significant and chronic decreases in core body temperature 
during the second half of the dark period during days 21-30 (p<0.05) and during the first 
half of the light period during days 14-30 (p<0.05) as well as during all 30 days during 
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Figure 3.4:  Impact of 400 PFU (n=13, grey bars) or 40,000 PFU (n=8, black bars) 
MuGHV infection on food intake and body weight in C57BL/6J mice.   Values are 
expressed as difference from vehicle body weight and food intake ± SEM.  Asterisk (*) 
indicates significant difference from vehicle (p<0.05).  Mice infected with 40,000 PFU 
















































Figure 3.5:  Dose comparison of body weight and food intake changes during chronic 
viral infection with 400 PFU (n=13, open circles) or 40,000 PFU (n=8, closed circles).  
Values are differences from HBSS for each dose (zero line) ± SEM.  Infected mice had 
significant differences in body weight during the first 7 days after inoculation (p<0.05).
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Figure 3.6: Impact of infection with 40,000 PFU MuGHV (n=8, filled circles) on sleep 
parameters in C57BL/6J mice compared to vehicle (empty circles).  Black bars signify 
the dark periods of the light:dark cycle.  Values are hourly means % recording time ± 
SEM.  Asterisks (*) indicate significant changes from HBSS.  Infected mice had 
significant increases in NREM on days 7-11 after inoculation, significant decreases in 
REM and significant increases in transitions on days 7-9 after inoculation and significant 
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Figure 3.7: Impact of vehicle (n=6, open circles) and LPS (n=6 filled circles) on core 
body temperature, NREM sleep and REM sleep in uninfected C57BL/6J mice.  Values 
are hourly means ± SEM.  Dark bars signify dark periods of the light:dark cycle.  
Asterisks (*) signify differences from vehicle.  LPS caused significant changes in 
temperature during hours 0-6 and 12-24, increases in NREM during hours 0-12 and 
decreases in REM during hours 7-12 and 24-30, as well as significant increases in 
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Figure 3.8: Impact of vehicle (n=13, open circles) and LPS (n=13, filled circles) in 
C57BL/6J mice infected with 400 PFU MuGHV on core body temperature, NREM, and 
REM sleep, transitions and delta power.  Values are hourly means ± SEM.  Dark bars 
signify dark periods of the light:dark cycle.  Asterisks (*) indicate significant differences 
from vehicle.  Infected mice had significant hypothermia during hours 0-12 and 24-30 
after injection, as well as significant increases in NREM during hours 0-12 and 24-36, 
significant increases in transitions during hours 0-30 and significant decreases in delta 
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Figure 3.9: Impact of vehicle (n=8, open circles) and LPS (n=8, closed circles) in 
C57BL/6J mice infected with 40,000 PFU MuGHV on NREM and REM sleep, 
transitions, and delta power.  Dark bars signify the dark portions of the light:dark cycle.  
Asterisks (*) signify differences from vehicle.  Infected mice had significant changes in 
temperature during the first 36 hours after injection with LPS, as well  significant 
increases in NREM during hours 0-12 and 24-30 after injection with LPS, significant 
decreases in REM during hours 12-18 and 24-30, significant increases in transitions 
during hours 0-24 after LPS. 
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Figure 3.10: Differences in core body temperature, NREM sleep and REM sleep and 
NREM delta power between C57BL/6J uninfected mice (n=6, open triangles) and 
C57BL/6J mice infected with 400 PFU (n=13, open circles) or 40,000 PFU (n=8, closed 
circles) of MuGHV.  Values are differences from respective vehicles (zero line) ± SEM.  
Asterisks (*) signify differences from 400 PFU infected and control mice, at (@) signs 
indicate differences between 40,000 infected mice and control mice, pound signs (#) 
indicate differences between 400 vs. 40,000 PFU infected mice.  Significant differences 
in temperature were found between 40,000 PFU mice and uninfected mice during hours 
0-6 and 13-18, and between both doses of infected mice at hours 7-12 and 19-24.  400 
PFU infected mice significantly differed from uninfected mice at hours 7-12.  Uninfected 
mice had significantly less changes in NREM during hours 24-30 after LPS and 
significantly different responses in REM during hours 0-6 and 13-18.  Mice infected with 
400 PFU had significantly less REM inhibition during hours 0-6 after LPS.  Infected 
mice groups had significantly different delta power changes in response to LPS during 
hours 12-18, and both 40,000 PFU and 400 PFU infected mice had significantly different 
















































Figure 3.11.  Copies of viral DNA in lung and spleen.  Mice were sacrificed during active 
phase (day 5) and peak of lung infection (day 9) as well as during latency (day 26) after 
inoculation with 40,000 PFU of MuGHV.  Virus was not detected in control mice (data 
not shown).  Asterisks (*) indicate significant differences from day 5 (p<0.05).   
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IMPACT OF MURINE GAMMAHERPESVIRUS INFECTION OF C57BL/6J 
MICE:  CENTRAL AND PERIPHERAL CYTOKINE RESPONSES TO 
CHRONIC VIRAL INFECTION 
 
Abstract 
INTRODUCTION: Infection of mice with murine gammaherpesvirus-68 
(MuGHV) is a model for human Epstein-Barr virus (EBV) infection.  Sleep-wake 
behavior, activity patterns, and body temperatures of mice inoculated with MuGHV are 
altered in a manner that mimics some facets of nighttime sleep disruptions and daytime 
fatigue of individuals infected with EBV or symptomatic for chronic fatigue syndrome.  
MuGHV induces synthesis and secretion of the cytokines interleukin (IL)-1β and IL-6 in 
the spleen and lung.  However, concentrations of cytokines in the central nervous system 
(CNS) during infection with this virus have not been widely investigated.  Because IL-
1β, IL-6 and other cytokines are implicated in the regulation of complex CNS processes, 
we hypothesize that alterations in sleep, activity and thermoregulation during chronic 
MuGHV infection may be mediated, in part, by actions of these cytokines.  As a first step 
in testing this hypothesis we determined concentrations of cytokines in discrete brain 
regions and in peripheral organs and serum during infection of mice with MuGHV.  We 
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also hypothesize that chronically infected mice will exhibit exacerbated cytokine 
responses to secondary immune challenge with lipopolysaccharide (LPS).  
 METHODS: Male C57BL/6J mice (n=6-8) were housed in microisolator cages 
under a 12:12 light:dark cycle at 29 ± 1ºC.  Control mice were inoculated intranasally 
(i.n.) with vehicle (Hank’s balanced salt solution, HBSS) and sacrificed after 4 days 
(n=16).  Separate groups of mice were inoculated with 400 or 40,000 plaque forming 
units (PFU) MuGHV and sacrificed 5, 9, or 26 days later.  Brain tissue (hypothalamus, 
hippocampus and cerebellum), blood, spleen, and lung were collected, snap frozen in 
liquid nitrogen, and stored for subsequent cytokine quantification.   
 RESULTS:  Cytokine concentrations in brain and the periphery were altered by 
MuGHV.  The pattern of cytokine responses in brain depended on the dose of MuGHV.  
Of interest, cytokine concentrations in brain and peripheral samples obtained from mice 
inoculated with 400 PFU of MuGHV changed in opposite directions early in the infection 
(day 5), with brain concentrations decreasing and concentrations in the periphery 
increasing.  Secondary immune challenge with LPS increased IL-1β and IL-6 
concentrations in CNS and peripheral structures of both infected and non-infected mice. 
 CONCLUSIONS: Despite an inability of MuGHV to invade the adult mouse 
CNS, central and peripheral cytokine concentrations were altered in infected mice.  The 
observation that central and peripheral cytokine concentrations change in opposite 
directions early during the course of infection suggests actions of feedback mechanisms 
between the CNS and peripheral organs.  Additional studies are needed to further assess 
mechanisms involved in post-viral fatigue of mice infected with MuGHV. 
Introduction 
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Epstein-Barr virus (EBV) is a ubiquitous human gammaherpesvirus (GHV) that 
establishes life-long latency in the host (Levitsky & Masucci, 2002).  EBV and other 
GHVs have two distinct phases, an active infectious phase, and a dormant (latent) phase.  
During active infection, GHVs are transmitted from the mucous membranes into the 
lungs where there is viral replication, a proliferation of lymphocytes, and a release of pro-
inflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, 
interferon (IFN)-γ, and IL-6 (Sarawar, Lee, & Giannoni, 2004; Sarawar et al., 1996; Jabs, 
Wagner, Schlenke, & Kirchner, 2000).  After a variable length period of active infection, 
the virus then travels within infected B cells through the lymph and enters the spleen.  
When the virus enters the spleen it alters its own DNA into an episome that halts viral 
gene expression (Nash & Sunil-Chandra, 1994).  The virus then becomes largely silent, 
dividing mainly with infected B-cells.  Although the virus replicates only sporadically 
during latent infection, cytokine levels remain chronically elevated (Nicholas, 2005).   
Numerous studies suggest EBV infection may be central to the pathogenesis of 
chronic fatigue syndrome (CFS) resulting from a secondary immune challenge that may 
cause permanent alterations in the immune system such as chronic cytokine release, and 
may perpetuate the state of chronic daytime fatigue (Glaser & Kiecolt-Glaser, 1998; 
Jones, 1988; Natelson et al., 1994).  Hypotheses that EBV is involved in the etiology CFS 
derive mainly from observations that individuals with CFS have higher antibody titers to 
EBV (Glaser et al., 2005; Matthews, Lane, & Manu, 1991; Swanink et al., 1995).   It is 
hypothesized that elevated circulating cytokines during EBV infection result in CFS and 
the post-viral symptoms of fatigue.  Patients with CFS have higher IL-1 and IL-6 levels 
that coincide with periods of fatigue (Cannon et al., 1999),  a relationship that does not 
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exist in normal subjects or in CFS patients during exercise-induced fatigue (Gupta, 
Aggarwal, & Starr, 1999).  Patients with CFS suffer other symptoms and often report 
poor quality nighttime sleep, characterized by insomnia, awakenings during the night, 
and unrefreshing sleep (Unger et al., 2004; Fukuda et al., 1994). EBV upregulates and 
sustains IL-6 production in human B-lymphocytes during infection (D'Addario, Ahmad, 
Morgan, & Menezes, 2000).  IL-6 is implicated in several human sleep disorders that are 
characterized by excessive daytime sleepiness and fatigue, including insomnia (Burgos et 
al., 2006; Okun et al., 2004; Vgontzas, Papanicolaou, Bixler, & Chrousos, 1997; 
Vgontzas et al., 1999).   
Many responses to peripheral immune challenge, such as alterations in sleep, 
body temperature, activity and food intake, are mediated by cytokine actions in brain 
(Dantzer, 2001; Dantzer et al., 1998; Dantzer et al., 1999).  Pro-inflammatory cytokines 
such as IL-1β and TNFα regulate non-rapid eye movement (NREM) sleep (Opp, 2005; 
Krueger, Obal, Fang, Kubota, & Taishi, 2001) and are also principle mediators of the 
effects of GHV infection (Sarawar et al., 2004).  These cytokines induce sickness 
behavior in animals and humans, as manifest by fatigue, fever, malaise, and arthralgia 
(Dantzer, 2001; Dantzer et al., 1998; Dantzer et al., 1999; Vollmer-Conna et al., 2004); 
all symptoms of CFS. 
  Although cytokines have been implicated as mediators of some symptoms of 
EBV infection and CFS, mechanistic studies in humans are difficult due to variability in 
the extent of infection, genetic background, immune status, and the subjective nature of 
fatigue ratings (Glaser, Padgett, 2005; Hossain, 2005).   Murine GHV-68 (MuGHV) is 
widely regarded as a useful immunological model for EBV infection because it has 
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similar stages of active and latent infection, induces similar host-immune responses, has 
similar host immune evasion tactics, and shares genetic structure (Blackman & Flano, 
2002; Flano, Woodland, & Blackman, 2002).  MuGHV alters the secretion of cytokines 
implicated in the regulation of sleep, which may contribute to a state of chronic fatigue 
(Olivadoti, in preparation).   
Whereas studies of MuGHV infection as an immunological model for EBV 
infection demonstrate similar patterns of cytokine release in the lung and spleen between 
EBV and MuGHV, no studies have determined the impact of MuGHV infection on  
concentrations of cytokines in the brain.  Furthermore, it is not known how central and 
peripheral cytokine concentrations relate to behavioral changes during different stages of 
viral infection.  In addition, many studies of EBV and MuGHV, have been conducted in 
vitro using infected cell lines (Sarawar et al., 1996).  Although in vitro studies are useful 
in many respects, in vitro studies may not reflect concentrations of cytokines in freely-
behaving animals during specific phases of MuGHV infection.  We hypothesize that 
changes in CNS and/or peripheral cytokines will be associated with fatigue and 
alterations in behavior during infection with MuGHV and secondary immune challenge.  
We focus on brain regions that have well-established roles in sleep, fatigue, and 
thermoregulation, including the hypothalamus, brainstem, and hippocampus (Opp, 2005; 
Krueger et al., 2001), and on peripheral organs that are most likely to be effected by the 
virus.  These peripheral organs include lung and spleen samples from infected and 
uninfected mice.  We now report that infection of mice with MuGHV alters cytokine 





Adult male (22-30g) C57BL/6J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  Mice were individually housed in microisolator cages and 
kept on a 12:12 hour light:dark cycle at an ambient temperature of 29 ± 1º C.  Water and 
rodent chow (Lab Diet 5001, PMI Nutrition International, Brentwood, MO) were 
provided ad libitum.  All procedures were approved by the University of Michigan 
Committee on Care and Use of Animals in accordance with the US Department of 
Agriculture Animal Welfare Act and the National Institutes of Health policy on Humane 
Care and Use of Laboratory Animals. 
 
Viral Preparation and Inoculation Procedure 
Viral stock of MuGHV-68 (8.2 x 105 PFU/mL, Blackman Lab, Trudeau Institute) 
was stored at -80º C and thawed just prior to use.  To achieve a 400 PFU dose the stock 
was diluted to by adding 170 μL of virus to 10 mL of HBSS.   50uL of straight stock was 
used to inoculate mice in the 40,000 PFU dose group. Mice were lightly anesthetized 
with isoflurane and held upright by the scruff of the neck while 30 – 50 μl of fluid were 
placed into the nostrils (intranasal, IN) with a micropipette.  Approximately half of the 
liquid was injected into each nostril and mice were observed until waking from the 
anesthesia.     
 
Protocols 
The same protocols used in previous studies to determine the impact of MuGHV 
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infection of mice on sleep-wake behavior, activity, and body temperature was used in this 
study (Figure 4.1).  The time points at which animals were sacrificed in this study 
coincide with time points for which we collected data on behavior and thermoregulation.  
The animals used in this current study were housed in the same room under the same 
conditions as those used in previous studies conducted in our laboratory with this virus. 
 
Experiment I: Impact of MuGHV infection on central and peripheral cytokine 
concentrations in C57BL/6J mice. 
Mice were placed in microisolator cages containing a running wheel and allowed 
one week to habituate to the presence of the wheel.  After the habituation period, mice 
were given either 30 μL or 50 μL of vehicle (Hank’s balanced salt solution) i.n..  Four 
days later mice were inoculated IN with either 30 μL of vehicle containing 400 PFU of 
MuGHV or 50 μL of vehicle containing 40,000 PFU of MuGHV.  Mice given vehicle 
(n=8) were sacrificed four days after IN administration.  Mice given MuGHV were 
sacrificed at day 5 (n = 8), day 9 (n = 5), or day 26 (n = 8) after inoculation.   
 
Experiment II: Impact of MuGHV infection on central and peripheral cytokine 
concentrations in response to secondary challenge in C57BL/6J mice. 
Mice were inoculated IN with either vehicle, 400 PFU of MuGHV, or with 40,000 
PFU of MuGHV.  All mice were housed in their cages for 30 days post-inoculation.  At 
dark onset of day 31 post-inoculation, mice were injected intraperitoneally (IP) with 2 
mL of pyrogen-free saline (n = 8 / group) or with 10 μg of lipopolysaccharide (LPS, 
Escherichia coli serotype O111:B4, Sigma Aldrich, St. Louis, MO) in 2 mL of saline (n = 
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8 / group).  Approximately 6 h after IP injection, mice were anesthetized and a blood 
sample was taken into a vacutainer tube containing EDTA (BD, Franklin Lakes, NJ).  
Mice were then euthanized and the lungs, spleen, and brain regions (brainstem, 
hypothalamus, hippocampus) were removed.  All tissue samples were put in cryovials 
(VWR, West Chester, PA) and flash-frozen in liquid nitrogen before being stored at -80 
ºC.  Blood samples were spun for 20 minutes at 10,000 RPM at 4 ºC and plasma was 
removed and stored at -80 ºC.   
 
Sample preparation and cytokine determination 
Total protein was extracted from tissue samples (Hulse, Kunkler, Fedynyshyn, & 
Kraig, 2004) and concentrations determined using a BCA assay (Pierce, Rockford, IL).  
Protein amount was standardized to 200 μg for each sample.  All serum samples were 
standardized by loading 50 μL into the plate.  Cytokine concentrations were determined 
by using a multiplex assay (Bioplex; BioRad Laboratories, Hercules, CA) based on 
Luminex® suspension array technology.   Concentrations of IL-1β, IL-6, IFNγ and TNFα, 
were determined for all samples.  Lung and serum samples additionally were assayed for 
the chemokine RANTES (CCL5). 
 
Statistical analyses 
Statistical analyses were performed using SPSS v. 13.0 for Windows.  Data were 
evaluated using unpaired T-tests for between and within dose concentrations.  
Comparisons were made between conditions (vehicle, MuGHV dose) within each 
structure or sample.  An alpha level of 0.05 was accepted for all statistical tests as 
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indicating significant departures from control values.  Percent change [(experimental 




Infection of mice with MuGHV induced alterations in cytokine concentrations in 
brain, peripheral organs, and serum (Figure 4.2).  There were differences in cytokine 
concentrations in samples obtained at different time points from mice inoculated with 400 
PFU of MuGHV or 40,000 PFU of MuGHV.  Overall, the pattern of change in cytokine 
concentrations during the course of infection with this virus reflects a dynamic process in 
which profiles of cytokines are altered. 
 
Experiment I: Impact of MuGHV infection on central and peripheral cytokine 
concentrations in C57BL/6J mice. 
 
Spleen 
Splenic cytokine concentrations were altered during the course of infection with 
MuGHV (Figure 4.2).  Concentrations of IL-1β and IFNγ increased (p < 0.05) in spleens 
obtained from mice inoculated with 400 PFU MuGHV and sacrificed on day 9 post-
inoculation.  IFNγ remained elevated (p < 0.01) in samples obtained on day 26 post-
inoculation.  Cytokine concentrations in spleens obtained from mice inoculated with 
40,000 PFU MuGHV also were altered relative to samples obtained from control animals.  
IL-6 (p < 0.01) and IFNγ (p < 0.05) were elevated in samples obtained on days 9 and 26 
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post-inoculation, respectively.  IL-1β concentrations decreased (p < 0.01) in spleens 
obtained on day 5 post-inoculation with 40,000 PFU MuGHV.  Concentrations of IL-1β 
and IFNγ on day 9 after inoculation were proportionally higher (p < 0.05) in spleens 
obtained from mice inoculated with 400 PFU than from those obtained from mice 
inoculated with 40,000 PFU.  By day 26 post-inoculation, concentrations of IFNγ were 
greater (p < 0.05) and TNFα were lower (p < 0.001) in spleens from mice inoculated with 
40,000 PFU muGHV as compared to spleens from mice inoculated with 400 PFU. 
 
Lung 
Concentrations of cytokines in lung were also altered during the course of 
infection with MuGHV (Figure 4.5).  Lung samples from mice infected with 400 PFU 
had significantly higher RANTES concentrations (p=0.001, Figure 4.3) on day 26 
compared to lungs from control mice.  Lungs from mice infected with 40,000 PFU of 
MuGHV had significantly higher concentrations of IFN-γ on day 5 after viral inoculation 
(p<0.05), as well as significant higher concentrations of RANTES on day 9 (p<0.001) 
and 26 (p=0.001) after inoculation compared to concentrations in lungs from control 
mice.  Lungs from infected mice had significantly different concentrations of TNFα on 
day 26 (p<0.05), as well different concentrations of IFN-γ from lung samples taken on 
day 5 and 9 after infection (p<0.05).   
 
Brainstem 
Brainstem samples from mice inoculated with 40,000 PFU did not show 
significant differences in concentrations of cytokines compared to control mice.  
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However brainstem samples from mice inoculated with 400 PFU had significant 
differences in cytokine concentrations compared to samples from vehicle treated mice.   
Samples collected 5 days after infection from mice inoculated with 400 PFU had 
significantly higher concentrations of TNF-α (p<0.05) compared to brainstem samples 
from vehicle treated mice.  Samples collected from 400 PFU infected mice on day 9 had 
lower concentrations of IL-1β (p<0.05), IL-6 (p<0.01), IFN-γ (p=0.001), and TNF-α 
(p<0.001) than vehicle samples collected on day 9 after infection.  When comparing 
changes in concentrations in brainstem samples taken on day 9 after infection, samples 
from mice inoculated with 400 PFU of MuGHV had significantly lower concentrations of 
IL-6 (p<0.001), IL-1 (p<0.010), IFN-γ (p<0.001) and TNF-α (p<0.05) compared to 
samples taken from 40,000 PFU infected mice.   
 
Hippocampus 
Cytokine concentrations in hippocampus samples obtained from infected mice 
were significantly different compared to samples from uninfected mice and when 
comparing concentrations between doses (Figure 4.2).  Samples from mice infected with 
40,000 PFU had higher concentrations of IL-1β on day 9 and 26 after infection (p<0.05) 
and concentrations of IL-6 in hippocampus were significantly higher on day 5 (p<0.001), 
9 (p<0.05), and 26 (p=0.001) after inoculation with 40,000 PFU compared to 
hippocampus samples from uninfected mice.   Hippocampus samples from the 40,000 
PFU infected mice also had significantly higher concentrations of IFNγ on day 26 after 
inoculation compared to hippocampus samples of vehicle treated animals.  Hippocampus 
samples taken from mice inoculated with 400 PFU MuGHV had significantly higher 
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concentrations of IFNγ on day 9 (p<0.05) after infection, and higher concentrations in 
TNFα on days 9 and lower concentrations on day 26 after infection compared to samples 
from uninfected mice (p<0.05).  When comparing cytokine concentrations in 
hippocampus between doses of infected mice, samples from 40,000 PFU mice had 
significantly lower IL-6 and IL-1β concentrations collected on day 9 after infection 
(p<0.05), and significantly different values in TNF-α in samples collected on day 26 
(p<0.05).  In addition samples from 40,000 PFU mice had significantly different 
concentrations of IFN-γ on days 5, 9 and 26 after infection (p<0.05) compared to samples 
from mice infected with 400 PFU on the corresponding days of infection. 
 
Hypothalamus 
Hypothalamus samples taken from mice infected with 400 PFU had significantly 
lower concentrations of IL-1β collected on day 5 after inoculation (p<0.05) than control 
mice, as well as IL-1 (p<0.05), IL-6 (p<0.001), IFN-γ (p<0.05), and TNF-α (p<0.05) 
collected on day 9 after infection.  Samples taken from mice infected with 40,000 PFU 
had significant decreases in IL-1b on day 5 after inoculation.  Mice infected with 400 
PFU had significantly lower IL-1 levels than samples taken from mice infected with 
40,000 PFU taken on day 5 (p<0.01), as well as significantly lower IL-6 concentrations in 
samples taken on days 5 (p<0.01) and 9 (p<0.001) after inoculation.  IFNγ responses 
differed significantly between doses on day 9 (p<0.05) and day 26 (p<0.05) after 
infection.  In addition, TNF-α concentrations were significantly lower in samples from 
400 PFU infected mice on days 9 and 26 compared to their samples from mice infected 




Serum concentrations from infected mice differed from those of control mice.  IL-
1β and IL-6 concentrations were significantly higher in samples taken from 400 PFU on 
day 9 after infection and in samples from 40,000 PFU infected mice collected on day 5 
after infection compared to samples from vehicle mice (p<0.05, Figure 4.2).  IFNγ 
concentrations were significantly higher in samples taken on day 26 after inoculation 
with 400 PFU of MuGHV, and significantly increased in samples taken from mice 
inoculated with 40,000 PFU collected on days 5 and 9 after infection compared to vehicle 
mice.  Samples taken from mice inoculated with 400 PFU of virus had significantly lower 
concentrations of RANTES (Figure 4.3) compared to serum from vehicle treated mice on 
day 5 after infection (p=0.001).  Concentrations of IL-1β and IL-6 were significantly 
different in samples from mice inoculated with 40,000 PFU on days 5 and 9 after 
inoculation compared to samples from mice infected with 400 PFU.  Samples from mice 
inoculated with 40,000 PFU MuGHV were also significantly different in concentrations 
of IFNγ and RANTES on day 5 after inoculation and in TNF in samples collected on day 
9 compared to samples from mice inoculated with 400 PFU MuGHV (p<0.05). 
 
Experiment II: Impact of chronic MuGHV infection in C57BL/6J mice on central and 
peripheral cytokine concentrations in response to secondary challenge  
 
Spleen 
Concentrations of IL-1β were significantly increased in spleen samples from 
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uninfected mice infected mice 6 h after LPS compared to samples from their respective 
vehicle control groups (p<0.001, Figure 4.4).  Spleen samples from mice infected with 
400 PFU also had significant increases in concentrations of IFN-γ (p<0.01) and IL-6 
(p=0.001, Figure 4.4) compared to 400 PFU inoculated and vehicle control mice.  Spleen 
samples from both doses of infected mice had significantly different concentrations in 
TNF-α compared to samples from uninfected mice in the response to LPS (p<0.01).  In 
addition, samples from mice inoculated with 400 PFU of MuGHV had significantly 
higher concentrations of IFN-γ    (p<0.05) compared to samples from uninfected mice.  
There were no significant differences in spleen cytokine concentrations when comparing 
samples from two dose groups to each other. 
 
Lung 
Lung samples from uninfected mice and mice inoculated with 400 PFU had 
significantly higher concentrations of RANTES after LPS compared to lung samples 
from their respective vehicle controls (Figure 4.5, p<0.015).  However, only samples 
from inoculated mice had significant increases in IL-1β concentrations in response to 
LPS compared to samples from the respective control groups (p<0.05 Figure 4.4).  Lung 
samples from mice inoculated with 400 PFU had significantly different cytokine 
concentrations of IL-6 compared to samples from uninfected mice (p<0.05). 
 
Brainstem 
Brainstem samples from uninfected mice and mice inoculated with both doses had 
significantly higher cytokine concentrations of IL-6 in response to LPS compared to 
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samples from the respective vehicle control groups (p<0.010 all groups).  Brainstem 
samples from uninfected mice and mice inoculated with 400 PFU also had significantly 
higher concentrations of IL-6 in response to LPS (p<0.05).  Brainstem samples collected 
from mice inoculated with 40,000 PFU were significantly higher in concentrations of IL-
1β and IL-6 compared to uninfected LPS treated mice samples (p<0.05).  Samples from 
mice inoculated with 400 PFU had higher concentrations of IL-6 in response to LPS 
compared to samples from mice inoculated with 40,000 PFU of virus (p<0.02). 
 
Hippocampus  
Infected mice did not demonstrate the same LPS-induced changes seen in 
uninfected mice in Hippocampal cytokine concentrations.  Hippocampus samples from 
uninfected control mice had significantly higher concentrations of IL-1 and IL-6 in 
response to LPS compared to sample concentrations from uninfected vehicle mice 
(p<0.010, Figure 4.4).  Samples from uninfected mice had significantly different cytokine 
concentration patterns of IL-1 (p<0.05) and IL-6 (p<0.010) responses to LPS compared 
to samples collected from mice inoculated with 40,000 PFU. 
 
Hypothalamus 
Hypothalamus samples collected from uninfected mice and mice inoculated with 
400 PFU had significantly higher concentrations of IL-6 (p<0.05, Figure 4.4) in response 
to LPS compared to samples from their respective control groups.  Samples from 
uninfected mice had significantly less alterations in concentrations of IL-1 and IL-6 in 
response to LPS compared to samples from mice inoculated with 400 PFU (p<0.05).  In 
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addition, hypothalamus samples from uninfected mice had significantly different TNF-α 
concentration response pattern when compared to samples from 40,000 PFU inoculated 
mice (p<0.010).  Samples from mice infected with 400 PFU had significantly larger TNF 
concentration increases in response to LPS compared to samples from 40,000 PFU 
inoculated mice (p<0.01). 
 
Serum  
Serum samples collected from uninfected mice had significant changes in 
concentrations of IL-1β, IL-6, IFNγ, and TNF-α in response to LPS compared to vehicle 
mice (p<0.05, Figure 4.4).  Samples collected from mice infected with 400 PFU MuGHV 
had significant changes in IL-1β, IL-6, and IFNγ in response to LPS compared to samples 
from infected vehicle mice.  Samples from mice inoculated with 40,000 PFU had 
significant changes in IL-1β compared to samples from infected vehicle mice.  In 
addition, samples from both uninfected and infected mice had significant changes in 
concentrations of RANTES in response to LPS compared to their respective vehicle 
groups (p<0.05, Figure 4.5).  Comparing cytokine concentrations in response to LPS, 
samples from non-infected mice had significantly different changes in IL-6, IFN, and 
TNF-α compared to samples from mice infected with 400 PFU of MuGHV (Figure 4.4 
p<0.05) and RANTES (Figure 4.5, p<0.05).  Samples from uninfected mice had 
significantly different changes in concentrations of TNF-α in response to LPS compared 
to samples from mice inoculated with 40,000 PFU MuGHV.  Concentrations of RANTES 
in serum samples in response to LPS significantly differed between different dose groups 




Infected mice have different response patterns in cytokine concentrations at 
different points of infection depending on the dose of infection, indicating a dose-specific 
response that is less clearly defined than previously suggested.  However an interesting 
caveat in these findings is that cytokines that are normally pyrogenic and fatigue-
inducing, including IL-1β, IL-6 and IFNγ are elevated in peripheral organs, yet 
suppressed in CNS tissues at times of chronic hypothermia and fatigue, suggesting 
interactions between central and peripheral systems to modulate complex behaviors in 
response to viral infection.  Significant increases in IL-6 on day 9 after infection of 
40,000 PFU could explain the significant decreases in food intake, body weight and 
activity.  However increases in RANTES in mice inoculated with 40,000 PFU MuGHV, 
which should normally cause fever (Tavares, et al., 2000), occurs at a time of pronounced 
hypothermia in these mice.  These differences in cytokine changes in response to 
infection and secondary immune challenge may explain differences in dose-related 
behavioral responses to infection.  Yet pro-inflammatory and pyrogenic cytokines, such 
as IL-1β and IL-6 are high in both uninfected and viral-inoculated animals in response to 
LPS, yet create different resulting body temperature and sleep profiles.  These results 
suggest that there is more at play in this virus causing changes in behavior than simply 
cytokine interaction, and cytokine concentrations in samples from freely-behaving 
animals are much more dynamic than in vitro samples.   
Patterns of sleep-wake behavior, activity, and body temperature of mice infected 
with MuGHV are altered in a manner that mimics some facets of nighttime sleep 
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disruptions and daytime fatigue of individuals infected with EBV or symptomatic for 
chronic fatigue syndrome (Olivadoti, et al., 2007; Chapter 3).  The peak of active 
infection in lungs of mice inoculated with MuGHV occurs between days 7 – 14, after 
which the virus becomes latent in the spleen (Flano, et al., 2002).  Recent behavioral data 
demonstrate that the time course of infection with 40,000 PFU of MuGHV, in particular 
the peak of active infection in the lung, is associated with significant changes in wheel 
running activity, core body temperature, food intake and body weight (Olivadoti, Chapter 
3).  Wheel running of mice infected with 400 PFU of MuGHV or with 40,000 PFU of 
MuGHV progressively decreases during infection and there are chronic persistent 
changes in core body temperature (Olivadoti, in preparation).  Mice infected with 
MuGHV also have altered responses to secondary immune challenge with LPS, including 
abnormal patterns of body temperature and alterations in sleep-wake behavior (Olivadoti, 
Chapter 3).   
Pro-inflammatory cytokines, such as IL-1β, TNF-α, IFNγ and IL-6 induce 
sickness behavior, as manifest by fatigue, fever, malaise, and arthralgia (Dantzer, 2001; 
Dantzer et al., 1998; Dantzer et al., 1999; Vollmer-Conna et al., 2004).  In addition they 
also regulate changes in sleep in response to pathogens, such as fragmentation of sleep, 
increases in NREM and decreases in REM sleep (Krueger, Toth, Opp, Kimura-Takeuchi, 
& Kapás, 1991, Opp, 2005).    
Infection with MuGHV alters cytokine synthesis and secretion in a manner that 
varies with the stage of infection.  The active phase of MuGHV infection is associated 
with splenic production of IL-1β, IL-2, IL-6, IL-10 and IFN-γ (Sarawar et al., 1996).  
IFNγ is vital for clearance of virus from the lung via the induction of cytotoxic T cells, 
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natural killer cells, and macrophages and controls the latent phase by curtailing viral 
reactivation from latency (Dutia, Clarke, Allen, & Nash, 1997, Sarawar et al., 1997).  IL-
6 is present in elevated concentrations in blood during active MuGHV infection (Sarawar 
et al., 1996).  IL-10 also influences MuGHV pathogenesis.  For example, IL-10 knockout 
mice have reduced viral load in the spleen yet increased splenomegaly (Peacock, et al., 
2001).  During latent infection of mice with MuGHV, IL-1β, TNF-α and IL-6 
concentrations are elevated (Sarawar et al., 1996).  In addition, MuGHV infection 
induces high levels of RANTES in the lung throughout infection (Weinberg, Lutzke, 
Alfinito, & Rochford, 2004).    
Whereas many studies have focused on peripheral cytokines as mediators of 
behavioral responses to infection, our results suggest that central mechanisms may also 
be important in regulating behavioral responses to MuGHV.  Although this virus does not 
infect the central nervous system when given i.n. (Terry, Stewart, Nash, & Fazakerley, 
2000), central structures do respond to infection with MuGHV as evidenced by changes 
in brain-regulated behavior and physiological processes during infection (Olivadoti, 
Chapter 3).  For example, during the peak time frame of active infection, inoculated mice 
begin to show significant chronic fatigue and decreases in body weight and food intake, 
which coincides with increases in IL-1β and IL-6 in serum.  However, cytokine 
concentrations do not follow chronic patterns along with behavioral changes.  In addition, 
in mice inoculated with 400 PFU of MuGHV, concentrations of cytokines in brain 
decrease while cytokine concentration in peripheral samples increase.  It is possible that 
infected mice may have developed a low-level infection in the CNS that has not been 
detected by previous studies.  However it is more plausible that the changes in opposite 
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directions of central and peripheral concentrations of cytokines and the dynamic changes 
of cytokine concentrations despite chronic behavioral changes suggest possible negative 
feedback inhibitory mechanisms, such interaction with the hypothalamic pituitary adrenal 
(HPA) axis, are involved in the complex behavioral and physiological processes induced 
by this virus.  
The HPA axis and immune system, particularly cytokines, work together through 
negative feedback mechanisms during infection to stop the ill-effects of chronic immune 
activation.  Many studies have shown that cytokines such as IL-1β, IL6, TNFα, IFN-γ 
can alter the axis at all levels—from the release of corticotrophin releasing hormone 
(CRH) to adrenocorticotropin hormone (ACTH) in the brain, and finally to cortisol 
release from the adrenals, causing inhibition of these same cytokines at all levels 
depending on where concentrations are highest [reviewed in (Silverman, Pearce, Biron, & 
Miller, 2005)].  Thus it is plausible that the HPA axis is the moderator between peripheral 
and central cytokines, resulting in central inhibition during times of heightened peripheral 
release due to the peripheral nature of the virus. 
 In sum, our data demonstrate changes in both central and peripheral cytokines in 
response to infection with MuGHV.  The dynamic relationship between central and 
peripheral cytokines and their impact on behavior are largely unclear, as many cytokines 
can have opposite effects of each other and play many different roles in physiology.  
Further studies are needed to understand the impact of physiological and immune 
changes in viral infection on behavior, including other mediators, as well as arousal and 









Figure 4.1. Graphic representation of protocol used to determine cytokine concentrations 
in brain and peripheral samples obtained from mice inoculated with MuGHV.  Arrows 
indicate time points of the study at which mice were sacrificed.  Control mice were 
sacrificed 4 days after vehicle administration (HBSS), 5-, 9- or 26 days after inoculation 
with MuGHV.  In addition, separate groups of chronically-infected mice were sacrificed  
24 h after intraperitoneal injection of pyrogen-free saline (vehicle), or 6 hours after 
intraperitoneal injection of 10 μg bacterial lipopolysaccharide injection. 
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Figure 4.2: Impact of MuGHV infection of C57BL/6J mice on concentrations of IL-1β, 
IL-6, IFNγ and TNFα in spleen (S), lung (L), hippocampus (HI), hypothalamus (HY), 
and serum (SE) in mice infected with 400 PFU (grey bars, n=6-8) or 40,000 PFU (black 
bars, n=6-8) MuGHV. Values are expressed as percent change (± SD) relative to samples 
obtained from control animals.  Asterisks (*) indicate significant differences from vehicle 

































Figure 4.3: Impact inoculation of C57BL/6J mice with 400 PFU (grey bars) or 40,000 
PFU (black bars) of MuGHV on concentrations of RANTES in lung and serum. Values 
are expressed as percent change (± SD) from values from samples obtained from control 
animals.  Asterisks (*) indicate significant differences from vehicle concentrations, pound 
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Figure 4.4: Impact of intraperitoneal injection of 10 μg lipopolysaccharide on IL-1, IL-6, 
IFNγ and TNFα concentrations in uninfected mice (white bars), mice  inoculated with 
400 PFU of MuGHV (grey bars), or mice inoculated with 40,000 PFU of MuGHV (black 
bars).  Values are presented as percent change (± SD) from concentrations detected in 
samples obtained from control animals.  S: spleen; L: lung; HI: hippocampus: HY: 
hypothalamus; SE: serum.  Asterisks (*) indicate significant differences from vehicle, 
pound signs (#) signify differences between doses, cross signs (†) indicate difference 




































Figure 4.5: Impact of 10 μg lipopolysaccharide on RANTES concentrations in lungs 
obtained from uninfected mice (white bars), mice inoculated with 400 PFU of MuGHV 
(grey bars), or mice inoculated with 40,000 PFU MuGHV (black bars) in lung (A) and 
serum (B).  Values are presented as percent change (± SD) from those obtained from 
samples of lung from control animals.  Asterisks (*) indicate significant differences from 
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Implications of MuGHV as a model for Epstein-Barr virus infection 
Many people in the world that have been exposed to EBV are at risk for chronic 
fatigue due to this virus, as well as resulting conditions such as CFS and depression 
(Rickinson et al., 2001; Mandell et al., 1995).  However not everyone who becomes 
infected with EBV ends up with chronic fatigue or CFS.  Due to the difficulty of studying 
EBV and chronic post-viral fatigue, animal models are needed to study these two 
conditions in a controlled setting.  Past research has demonstrated the immunological 
efficacy of using MuGHV as a model for human EBV (Blackman & Flano, 2002; Flano 
et al., 2002), and now our results have expanded their model to examine issues of post-
viral behavior and fatigue to model EBV and resulting behaviors.  Our results show 
behavioral correlates with infection, such as fatigue, changes in body temperature, and 
sleep, as well as abnormal responses to secondary immune challenge.  These results 
mimic the human condition of fatigue and the severity of these changes increase 
according to inoculation dose.  Thus these results further the notion that MuGHV is a 
well-adapted model for studying EBV and the pathogenesis of resulting chronic fatigue 
that occurs in some infected humans.  
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Compartmentalization of the virus and behavioral correlates 
PCR results suggest that current time frames of infection in specific 
compartments of the body (i.e. lung vs. spleen) and resulting behaviors may be dose-
specific.  Thus more research on dosages of viral infection and the resulting behaviors 
may lead us to a better understanding of the interaction between immune responses to 
GHV infection and subsequent behavioral changes.   Mice infected with MuGHV have 
sleep, temperature and body weight changes that are specific to the peak of viral infection 
of the active phase; however changes in these behaviors become more generalized during 
the latent phase.     
 
Modeling of chronic post-viral fatigue 
The resulting fatigue due to infection in our mice only occurs in voluntary wheel-
running activity, while facultative activity, such as grooming, feeding, drinking, and 
nesting remains unchanged.  This is an important facet of post-viral fatigue, as the 
definition of fatigue for CFS is a reduction in daily voluntary activity (Fukuda et al., 
1994).  Many CFS patients are able to maintain productivity in their work life, but find 
that it is difficult to maintain social relationships and an active family life (Rakib et al., 
2005).  However, like all syndromes, symptoms vary depending on the patient.  In our 
model, mice infected with different doses of MuGHV have different degrees of fatigue, 
which suggests that the amount of virus that patients receive could affect their resulting 
fatigue.  However further studies are needed to understand what other factors affect the 
resulting fatigue, including genetics, stress, and status of the immune system.   
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Thermoregulatory changes in mice infected with MuGHV 
Infected mice have distinct changes in thermoregulation during the different 
stages of viral infection that vary by dose.  However the paramount similarity is a 
hypothermia that is persistent into latency, suggesting changes in central 
thermoregulatory mechanisms, which also occurs in humans with CFS.  However in CFS 
patients report chronic low-grade fevers, which raises the question of the physiological 
role of hypothermia in mice compared to fevers in humans.  In addition, studies in 
adolescents with CFS have suggested abnormalities in catecholaminergic-dependant 
thermoregulatory mechanisms (Wyller et al., 2007) but the pathogenesis of these 
differences are still unknown.  The role and mechanisms of hypothermia in mice are 
well-debated and still yet unclear, and thus makes it difficult for us to apply our results to 
humans with post-viral fatigue.  More studies are needed to compare chronic 
hypothermia in MuGHV infected mice and chronic low-grade fevers in patients with 
post-viral fatigue.   
 
Sleep Correlates 
While mice infected with a high dose of MuGHV showed significant changes in 
sleep after infection that are similar to what is reported in EBV, these changes were 
limited to the acute phase of infection in the lung.  However mice also lacked insomnia or 
fragmentation of sleep that could explain chronic fatigue, which makes MuGHV-induced 
changes a more pure fatigue state.  It is unclear what generates chronic sleep problems in 
post-viral fatigue.  Perhaps the sleep complaints in chronic fatigue patients are a factor of 
co-morbid conditions such as depression or other conditions such as fibromyalgia or 
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arthritis.  Future studies would be helpful in understanding which changes cause chronic 
sleep variations in these patients. 
Cytokine changes during infection 
Our results replicated results of previous studies with increases in IL-1 and IL-6 
in the lung and spleen throughout infection.  However our results from central cytokines 
painted a much more complicated picture, suggesting both peripheral and central 
mechanisms at play during infection despite lack of viral invasion in the brain found in 
previous studies using adult mice (Terry, Stewart, Nash, & Fazakerley, 2000).  Increases 
in peripheral cytokines (in the spleen and lung) occurred during simultaneous decreases 
in central cytokines (in the brainstem, hippocampus and hypothalamus) suggesting 
feedback mechanisms that must be able to communicate across the blood-brain-barrier.  
In addition, cytokine profiles across infection were different when comparing two 
different doses, suggesting that there is no clear general answer to how to address 
cytokine dysregulation in MuGHV infection.  With the addition of complicated central 
cytokine profiles, there is no clear way to explain the thermoregulation changes, fatigue, 
and sleep disturbances in mice infected with MuGHV.  For instance, there may be many 
different cytokines at play controlling hypothermia in 40,000 PFU mice, due to the large 
decreases in core body temperature at peak of infection in the lung, and subsequent 
chronic (but less severe) hypothermia after clearance from the lung.  In addition, many 
cytokines can be both pyrogenic and cryogenic, or have a bi-phasic effect depending on 
the challenge, room temperature, and mouse strain used  [reviewed in (Romanovsky et 
al., 2005)].  Thus it is prohibitive to draw conclusions about the role of cytokines in 
behavioral changes in MuGHV infection.  Cytokine inhibitors and knock-out studies 
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would be helpful in understanding the role of central and peripheral cytokines in changes 
in behaviors during and after infection.    
 
Abnormal Responses to Secondary Immune Challenge  
Our results show dose-dependant changes in body temperature, sleep, and fatigue 
in response to secondary immune challenge, further demonstrating chronic 
immunological changes by viral infection.  This is an important consideration in 
modeling, considering that while much of the population is exposed to EBV, there have 
been no studies to date of how latently infected individuals react to subsequent immune 
challenge.  Understanding how EBV changes the immune system is important to 
understand how future illnesses and insults can affect individuals and applying proper 
treatments for these individuals after EBV infection to prevent chronic immune changes 
that can negatively affect responses to further insults.    It is possible that global chronic 
immune changes could prime an individual to become chronically fatigued, however 
since all of our mice in these studies became fatigued, more studies are needed to explain 
the mechanisms of immune changes and what variables are important in the resulting 
changes due to viral infection. 
 
Global implications and conclusions 
Chronic fatigue is a disabling condition that is widespread and emotionally and 
physically devastating (Rakib et al., 2005).  Due to the connection between EBV and 
CFS, and the high rates of exposure to EBV in the population, an alarming amount of the 
population is at risk for developing post-viral fatigue at some point in their lifetime.  
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Currently the mechanism of fatigue after a viral insult is largely unknown, however our 
studies show fatigue after a virus could be due to viral-induced changes in cytokines.  
Further studies are needed to understand the impact of the virus on resulting immune 
responses, and the impact of the virus on other systems involved in arousal, sleep, and 
thermoregulation, such as sympathetic and parasympathetic systems and the 
hypothalamic pituitary axis.  It is also unclear what causes individuals to have a short 
post-viral fatigue state that lasts months and then slowly remits versus those who never 
have a remission of fatigue.  Further longitudinal studies in humans are needed to explain 
this phenomenon.   
Due to the many difficulties in studying EBV in humans as mentioned above, our 
studies have established MuGHV as a mouse model for studying post-viral fatigue in an 
objective and controlled manner.  This model will allow us to address issues such as the 
impact of genetics, environment, social and physical stress, and immune status on the 
pathogenesis of fatigue after EBV.  In addition, this model allows for further study of the 
mechanism for altered immune responses to subsequent immune challenge, and can be 
enhanced to include a broader range of pathogens.  The results mentioned previously 
point more directly to substances that can inhibit somnogenic cytokine release centrally 
or peripherally, or block their effects.  There are very few treatments for chronic fatigue, 
and they include mild exercise, behavioral therapies and anti-viral medications 
(Chambers, Bagnall, Hempel, & Forbes, 2006), as well as cytokine inhibitors (Kerr et al., 
2007).  This mouse model could be used to investigate treatments and prophylactics, 
including vaccines, cytokine inhibitors, viral inhibitors at specific time points during the 
viral infection, and behavioral tactics such as forced exercise, to decrease the fatigue and 
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other behavioral changes seen as a result of the virus.   In addition, it is currently 
unknown how factors such as sleep, sleep quality, stress, and other environmental factors 
impact both the resulting behavior and immunology of the host in relationship to dose.  
This model would prove invaluable for studying these factors in a controlled 
environment.   
The use of MuGHV can also enhance our understanding of how chronic fatigue 
can lead to depression.  This model could be used to understand the emotional toll of 
chronic fatigue through simple behavioral and motivational tasks, therefore approaching 
better ways to prevent and treat depression in chronic fatigue patient populations.  In 
addition, it could be used to test the intellectual toll on mice, as many chronic fatigue 
patients report “brain fog” and problems with learning (Vollmer-Conna et al., 1997).  
Overall this model creates a fantastic opportunity to research the devastating effects of 
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Statistical values for data presented in Chapters 3 and 4.  Presented are degrees of 
freedom, F-values and resultant p values for those parameters that achieved statistical 
significance. 
 
Table A1.  Wheel running activity and temperature statistics during infection. 
Variable Dose Day/Week Comparison Time Period (hrs) df  F-value p-Value 
wheel 40,000 PFU Week 1 HBSS 1_12 21 3.85 0.004 
wheel 40,000 PFU Week 2 HBSS 1_12 21 3.85 0.002 
wheel 40,000 PFU Week 3 HBSS 1_12 21 3.85 0.002 
wheel 40,000 PFU Week 4 HBSS 1_12 21 3.85 0.002 
wheel 40,000 PFU Week 1 HBSS 13_24 16 17.12 0.000 
wheel 40,000 PFU Week 2 HBSS 13_24 16 17.12 0.000 
wheel 40,000 PFU Week 3 HBSS 13_24 16 17.12 0.000 
wheel 40,000 PFU Week 4 HBSS 13_24 16 17.12 0.000 
  wheel 400 PFU Week 3 HBSS 7_12 40 3.14 0.008 
wheel 400 PFU Week 4 HBSS 7_12 55 3.15 0.001 
wheel 400 PFU Week 1 HBSS 19_24 24 2 0.012 
wheel 400 PFU Week 2 HBSS 19_24 24 2 0.026 
wheel 400 PFU Week 3 HBSS 19_24 24 2 0.045 
wheel 400 PFU Week 4 HBSS 19_24 24 2 0.044 
temp 40,000 PFU Day 9 HBSS 7_12 18 8.7 0.004 
temp 400 PFU Week 3 HBSS 13_18 27 8 0.007 
temp 400 PFU Week 4 HBSS 13_18 27 8 0.000 
temp 400 PFU Week 2 HBSS 19_24 27 7.1 0.003 
temp 400 PFU Week 3 HBSS 19_24 27 7.1 0.004 
temp 400 PFU Week 4 HBSS 19_24 27 7.1 0.000 
wheel 400 PFU Week 3 HBSS 7_12 40 3.2 0.030 







Table A2. Sleep variable statistics during infection. 
Variable Dose Day Comparison Time Period (hrs) df  F-value p-Value 
Nrem 40,000 PFU Day 9 HBSS 1_6 28 12.9 0.000 
Rem 40,000 PFU Day 9 HBSS 1_6 28 5.1 0.014 
Wake 40,000 PFU Day 9 HBSS 1_6 28 12.5 0.010 
Transitions 40,000 PFU Day 9 HBSS 1_6 28 9 0.007 
Nrem 40,000 PFU Day 9 HBSS 7_12 26 14.4 0.000 
rem  40,000 PFU Day 9 HBSS 7_12 22 5.5 0.041 
Wake 40,000 PFU Day 9 HBSS 7_12 26 15.3 0.000 
Transitions 40,000 PFU Day 9 HBSS 7_12 25 12 0.014 













Table A3.  Food intake and Body weight statistics during infection. 
 
Variable Dose Day/Week Comparison Time Period (hrs) df  F-value p-Value 
weight 40,000 PFU week 2 HBSS n/a 8 17.1 0.002 
food intake 40,000 PFU day 8 HBSS 13-16 28 5.9 0.014 
food intake 40,000 PFU day 9 HBSS 13-16 28 5.9 0.033 
food intake 40,000 PFU day 10 HBSS 13-16 28 5.9 0.006 
body weight 40,000 PFU day 9 HBSS 13-16 12 5.98 0.038 
body weight 40,000 PFU day 10 HBSS 13-16 12 5.98 0.018 
food intake 40,000 PFU day 8 HBSS 13-16 28 5.9 0.014 
food intake 40,000 PFU day 9 HBSS 13-16 28 5.9 0.033 
food intake 40,000 PFU day 10 HBSS 13-16 28 5.9 0.006 
body weight 40,000 PFU day 9 HBSS 13-16 12 5.98 0.038 
  body weight 40,000 PFU day 10 HBSS 13-16 12 5.98 0.018 











Table A4.  Cage/wheel activity, and temperature statistics after LPS injection. 
Variable Comparison LPS DAY Comparison Hours df F value P-value 
cage 40,000 PFU 1 Saline 1_6 26 19.2 0.000 
cage 40,000 PFU 1 Saline 7_12 18 15.6 0.000 
cage 40,000 PFU 2 Saline 1_6 26 19.2 0.000 
cage 40,000 PFU 2 Saline 7_12 18 15.6 0.015 
wheel 40,000 PFU 1 Saline 1_6 9.2 20 0.000 
wheel 40,000 PFU 2 Saline 1_6 9.2 20 0.024 
cage 400 PFU 1 Saline 7_12 54 13 0.000 
cage 400 PFU 2 Saline 13_18 54 10 0.038 
temp 400 PFU 1 Saline 1_6 55 3.6 0.001 
temp 400 PFU 1 Saline 7_12 38 3.6 0.003 
wheel 400 PFU 1 Saline 1_6 70 11.3 0.000 
wheel 400 PFU 1 Saline 7_12 63 7.9 0.000 
wheel 400 PFU 2 Saline 1_6 70 11.3 0.000 












Table A5.  Within dose comparisons of sleep variables after Saline or LPS injection. 
Variable Comparison LPS DAY Comparison Hours df F value P-value 
nrem 40,000 PFU 1 Saline 1_6 28 27.6 0.000 
nrem 40,000 PFU 1 Saline 7_12 31 31.1 0.000 
nrem 40,000 PFU 2 Saline 1_6 42 27.6 0.001 
rem 40,000 PFU 1 Saline 1_6 42 6.95 0.001 
rem 40,000 PFU 1 Saline 13_18 34 13.2 0.000 
temp 40,000 PFU 1 Saline 1_6 7 3.6 0.024 
temp 40,000 PFU 1 Saline 13_18 7 34.7 0.000 
temp 40,000 PFU 1 Saline 19_24 9 7.2 0.000 
temp 40,000 PFU 1 Saline 7_12 28 15.4 0.000 
temp 40,000 PFU 2 Saline 1_6 7 3.6 0.015 
temp 40,000 PFU 2 Saline 13_18 7 34.7 0.000 
temp 40,000 PFU 2 Saline 19_24 9 7.2 0.000 
temp 40,000 PFU 2 Saline 7_12 28 15.4 0.000 
temp 40,000 PFU 3 Saline 13_18 7 34.7 0.000 
temp 40,000 PFU 3 Saline 19_24 9 7.2 0.000 
temp 40,000 PFU 3 Saline 7_12 28 15.4 0.000 
temp 40,000 PFU 4 Saline 13_18 7 34.7 0.000 
temp 40,000 PFU 4 Saline 19_24 9 7.2 0.000 
temp 40,000 PFU 4 Saline 7_12 29 15.4 0.003 
temp 40,000 PFU 5 Saline 13_18 7 34.7 0.000 
temp 40,000 PFU 5 Saline 19_24 10 7.2 0.001 
temp 40,000 PFU 5 Saline 7_12 30 15.4 0.015 
transitions 40,000 PFU 1 Saline 1_6 37 35.4 0.000 
transitions 40,000 PFU 1 Saline 7_12 38 15.4 0.000 
transitions 40,000 PFU 1 Saline 13_18 27 11.8 0.000 
transitions 40,000 PFU 1 Saline 19_24 16 13.1 0.000 
wake 40,000 PFU 1 Saline 7_13 32 27.5 0.000 
nrem 400 PFU 1 Saline 1_6 20 7.3 0.002 
nrem 400 PFU 1 Saline 7_12 18 16 0.000 




nrem 400 PFU 3 Saline 19_24 20 57 0.000 
nrem 400 PFU 4 Saline 13_18 20 56.5 0.000 
nrem 400 PFU 4 Saline 19_24 20 57 0.000 
nrem 400 PFU 5 Saline 13_18 20 56.5 0.000 
nrem 400 PFU 5 Saline 19_24 20 57 0.000 
rem 400 PFU 3 Saline 13_18 8 9.2 0.003 
rem 400 PFU 3 Saline 19_24 13 9 0.003 
rem 400 PFU 4 Saline 13_18 8 9.2 0.048 
rem 400 PFU 4 Saline 19_24 17 9 0.048 
rem 400 PFU 5 Saline 13_18 8 9.2 0.008 
rem 400 PFU 5 Saline 19_24 13 9 0.008 
transitions 400 PFU 1 Saline 1_6 20 19 0.000 
transitions 400 PFU 1 Saline 13_18 17 20 0.000 
transitions 400 PFU 1 Saline 19_24 17 20 0.000 
transitions 400 PFU 1 Saline 7_12 21 27.3 0.000 
transitions 400 PFU 3 Saline 13_18 20 20 0.001 
transitions 400 PFU 3 Saline 19_24 20 20 0.001 
transitions 400 PFU 4 Saline 13_18 20 20 0.029 
transitions 400 PFU 4 Saline 19_24 20 20 0.029 
transitions 400 PFU 5 Saline 13_18 17 20 0.009 
transitions 400 PFU 5 Saline 19_24 18 20 0.009 
wake 400 PFU 1 Saline 1_6 21 7 0.003 
wake 400 PFU 1 Saline 7_12 18 14.9 0.000 
wake 400 PFU 3 Saline 13_18 20 58 0.000 
wake 400 PFU 3 Saline 19_24 23 58 0.000 
wake 400 PFU 4 Saline 13_18 20 58 0.000 
wake 400 PFU 4 Saline 19_24 23 58 0.000 
wake 400 PFU 5 Saline 13_18 20 58 0.000 






Table A6.  Between dose comparisons of sleep variables after Saline or LPS injection. 
Variable Comparison LPS DAY Hours df F value P-value 
delta power 400 v 40,000 PFU 1 1_6 18 -5.6 0.000 
delta power 400 v 40,000 PFU 1 13_18 12 -3.1 0.009 
delta power 400 v 40,000 PFU 1 19_24 17 2.2 0.043 
delta power 400 v 40,000 PFU 1 7_12 17 -2.4 0.027 
rem 400 v 40,000 PFU 1 1_6 10 -2.4 0.035 
trans 400 v 40,000 PFU 1 1_6 10 -3.1 0.012 
trans 400 v 40,000 PFU 1 1_6 10 -3.2 0.009 
delta power Uninfected vs 40,000 1 1_6 11 -6 0.000 
delta power Uninfected vs 40,000 1 13_18 11 8.3 0.000 
delta power Uninfected vs 40,000 1 19_24 11 8.7 0.000 
deltapwr Uninfected vs 40,000 PFU 2 1_6 12 0.348 0.043 
nrem Uninfected vs 40,000 2 1_6 11 -2.5 0.029 
rem Uninfected vs 40,000 1 1_6 12 -2.5 0.028 
rem Uninfected vs 40,000 1 13_18 12 2.4 0.033 
trans Uninfected vs 40,000 1 1_6 12 -3.5 0.004 
trans Uninfected vs 40,000 1 7_12 12 -2.3 0.044 
delta power Uninfected vs 400 1 7_12 14 3.2 0.006 
delta power Uninfected vs 400 2 1_6 10 -3.1 0.044 










Variable Comparison LPS DAY Comparison df F value P-value 
food intake 40,000 PFU 4 SALINE 14 -2.9 0.012 
weight 40,000 PFU 1 SALINE 14 3.34 0.005 
weight 40,000 PFU 2 SALINE 14 2.3 0.041 
food intake 400 v 40,000 PFU 3 n/a 16 -2.3 0.034 
weight 400 v 40,000 PFU 1 n/a 13 7 0.000 
weight 400 v 40,000 PFU 3 n/a 8 -3.2 0.012 
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Table A7.  Within and between dose comparisons of food and body weight 
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